Hair Regrowth: The Honest Science of Hair Loss, Greying & What Actually Works
Hair regrowth, how to regrow hair, what DHT blockers do, which compounds are inflated, how to reverse grey hair naturally, plus wash-frequency by hair type.
Read the science- What this guide covers (and what it skips)
- The DHT paradox: same hormone, opposite outcomes
- The micro-tension theory: scalp tightness as inflammation amplifier
- What actually works for hair regrowth: the evidence tier
- Emerging treatments worth watching
- Stalled and failed: the cautionary tale
- Marketed but inflated: compound-by-compound honest verdicts
- The DHT-blocker honest read
- Why your hair greys: the modern picture
- Can grey hair be reversed? The honest, bounded answer
- The biomimetic dye honest tier: Hairprint vs Plantur Anti-Grey vs PPD
- Plantur 39 Anti-Grey vs hair dye vs leaving it alone: the buyer guide
- Beard greying: the case for and against dyeing
- The stress-cortisol-hair axis
- The metabolic angle: oxidative stress, mitochondria, and your hair
- How often should you actually wash your hair?
Most of the noise around hair regrowth is marketing layered over four or five molecules that actually move the needle.
0.0
hairs/cm-squared
minoxidil alone
0.0
hairs/cm-squared
weekly microneedling plus 5 percent minoxidil
The right-hand field took one extra step a week.
The evidence tierHair Regrowth, Honestly
The hair-product industry is meaningfully larger than the evidence supporting it. Most pages on hair regrowth and greying treat every ingredient as roughly equivalent. The evidence is not equivalent. This guide ranks treatments by RCT quality, names the failed ones (setipiprant 2018, botox for AGA in the 2024 JAAD RCT, most exosome injectables), grades compounds rather than brands (Plantur 39 caffeine line versus Plantur 39 Anti-Grey 5,6-DHI line, same brand and very different verdicts), and answers the practical questions: does Plantur 39 work, what actually counts as a real DHT blocker, can grey hair be reversed, what is the best hair dye for sensitive scalp use, and how often should you actually wash your hair.
The format is mechanism-first, evidence-graded, and direct. If a treatment has been superseded, that is named. If a brand has different evidence on different product lines, that is named too.
Three problems
What this guide covers (and what it skips)
This is a long article because hair regrowth, how to regrow hair, and reverse grey hair naturally are genuinely separate problems with different mechanisms, different evidence bases, and different honest answers. The plan below is the navigation map.
What actually works
If you want the short version: the strongest evidence for AGA hair regrowth is finasteride, minoxidil (topical or low dose oral minoxidil), and microneedling for hair loss layered on top of minoxidil.
Everything sold as a dht blocker sits in tiers below those, with saw palmetto being the only meaningful plant compound.
What is oversold
Hair vitamins, biotin shampoos, vitamins for hair loss, and most rosemary oil hair growth claims are either oversold or work mildly.
PRP for hair loss beats placebo but does not beat minoxidil on its own.
What nothing fixes yet
Greying is not currently reversible by any pill, although stress reduction can partially reverse stress and grey hair in a narrow window of middle-aged near-threshold subjects, and the biomimetic dye chemistry covered later (Plantur 39 Anti-Grey Effect, Hairprint) is closer to a working coverage solution than any supplement for grey hair or vitamin for grey hair on the market.
Everything this guide covers, in order
Pillars covered below: the DHT paradox and why scalp follicles see DHT differently from beard follicles, the micro-tension theory of mechanical scalp inflammation, an evidence-tier ranking of treatments that actually work, an emerging-treatments map (PP405, ET-02, clascoterone, GT20029, hair cloning, stem cells hair loss biology), an honest cautionary tale on stalled and failed treatments (setipiprant, botulinum toxin for AGA, PC-KUS, most exosomes hair growth clinics, red light therapy hair growth honest framing), the nutrafol review and viviscal review compound-level honest verdicts, the dual plantur 39 review (caffeine line versus Anti-Grey Effect line), pigment biology and the can you reverse grey hair bounded answer, the three-tier dye taxonomy with hairprint review context for permanent vs semi permanent hair dye decisions, the best beard dye question and is just for men safe with the FDA adverse-event picture, the metabolic and stress-cortisol axes of hair density loss, and finally how often should i wash my hair answered by hair type and condition (including how often should men wash hair, is shampoo bad for your hair, co washing hair, scalp oil management, and the no poo method).
If you came here looking for the answer to does plantur 39 work, how to reverse grey hair, stop hair from going grey, or whether caffeine shampoo does anything, the relevant sections are linked from this map and the answers are evidence-graded rather than brand-graded. The BellyProof framing throughout is mechanism-first, evidence-tier-graded, and explicit about which compounds, brands, and treatments have failed clinical testing in the last few years rather than quietly fading from press releases.
FREE AI TOOL See your BellyProof transformation before you start
Free AI body scan reads where you are now and projects you forward through fat loss and muscle building. No signup. 90 seconds.
Hair regrowth Mechanism
The DHT paradox same hormone, opposite outcomes
This section is the foundation for understanding dht hair loss, the broader question of dht and hair loss at the receptor level, and why hair miniaturization is the visible endpoint of an upstream signalling problem rather than a hormone problem.
IGF-1
TGF-beta1, TGF-beta2, DKK-1 IL-6
Ligand at the receptor
The same key, two different doors.
Dihydrotestosterone is the most androgenic signal your body produces, and it does two seemingly contradictory things at once. On your jaw, chest, axilla, and pubis, DHT is the conversion signal that takes a fine, lightly pigmented vellus hair and terminalizes it into a thick, deeply pigmented terminal hair. On the frontal and vertex scalp of a genetically susceptible man, the exact same molecule does the opposite: it drives the slow, generation-by-generation follicle miniaturization that defines androgenetic alopecia. Same hormone. Same bloodstream. Opposite outcomes. The useful way to hold this is that DHT is the messenger, not the villain. What differs between your beard and your hairline is not the signal, it is how each follicle's dermal papilla has learned to interpret that signal.
Why scalp follicles see more DHT in the first place
Two things stack the local androgen environment against your scalp before the interpretation step even begins. The first is enzyme density. 5-alpha reductase Type II, the isoenzyme that converts testosterone into DHT inside the follicle, is concentrated heavily in scalp dermal papilla cells. Hoffmann reported activity roughly an order of magnitude higher in balding scalp dermal papilla than in non-balding compartments elsewhere on the body Hoffmann R, Happle R. J Invest Dermatol. 1996 Hoffmann 1996. Your scalp follicles are not just bathed in circulating DHT, they are actively manufacturing more of it locally, in the very compartment that controls the hair cycle.
The second is receptor density. The androgen receptor is expressed at substantially higher levels in frontal and vertex balding dermal papilla than in occipital scalp or beard dermal papilla Inui & Itami. Exp Dermatol. 2013 Inui & Itami 2013. The androgen receptor gene also carries a CAG-repeat polymorphism in its N-terminal transactivation domain. Shorter CAG repeats produce a more transcriptionally sensitive receptor, and men with shorter AR CAG repeats are over-represented in early-onset androgenetic alopecia Ellis JA, Stebbing M, Harrap SB. J Invest Dermatol. 2001 Ellis 2001. Before any downstream biology fires, the balding scalp has more enzyme to make DHT, more receptor to bind it, and a receptor variant that is, on average, more reactive per molecule of ligand.
The flipped secretome: the part nobody explains
This is where the paradox actually lives, and it is the part that makes the popular shorthand 'DHT is bad for hair' technically wrong. When you stimulate beard dermal papilla cells with DHT in culture, they upregulate IGF-1, a pro-anagen, pro-proliferation growth factor that pushes the surrounding matrix keratinocytes to build a bigger, longer, darker hair shaft. When you stimulate balding frontal dermal papilla cells with the identical concentration of the identical molecule, they upregulate a completely different set of paracrine signals: TGF-beta1, TGF-beta2, DKK-1 (a Wnt-pathway inhibitor), and IL-6 Inui & Itami. Exp Dermatol. 2013 Inui & Itami 2013. Every one of those is anagen-suppressive. TGF-beta drives premature catagen entry. DKK-1 blocks the Wnt signalling that keeps the hair matrix in a proliferative state. IL-6 contributes to peri-follicular inflammatory tone.
The hormone is identical. The hormone concentration can be identical. The receptor it binds is the same gene product. What is different is the downstream secretome, the menu of paracrine factors the dermal papilla decides to release once the receptor is occupied. Your beard's dermal papilla translates androgen receptor activation into a grow signal. Your hairline's dermal papilla translates the same activation into a shrink signal.
That reframing matters because it changes what a rational treatment is supposed to do. The classic systemic approach (finasteride and dutasteride) works by suppressing 5-alpha reductase and crashing serum and tissue DHT. It does help androgenetic alopecia, because if you remove the ligand you silence the bad secretome. But it removes the ligand everywhere, which is why the same drugs reduce beard density, body hair density, and carry the well-documented sexual and mood side effect profile that makes a lot of men quit them. Scalp-localized strategies (topical finasteride and clascoterone, a topical androgen receptor antagonist that hit its Phase 3 endpoints) preserve beard and body DHT signalling and only blunt the receptor at the scalp. That is a smarter compromise.
The deeper move, and the one that organizes the rest of this article, is to stop trying to delete DHT at all and instead change how the scalp dermal papilla interprets it. If the secretome is what flipped, the secretome is what you want to flip back. Mechanical tension on the galea, chronic peri-follicular inflammation, fibrosis, and the local micro-environment are all upstream of which paracrine factors a dermal papilla cell chooses to release. That is the territory the next section opens. The BellyProof read on dht hair loss, simply, is that DHT is information and the dermal papilla is the interpreter, and changing the interpreter is the more durable lever than crushing the signal everywhere it travels.
Hair regrowth Contrarian
The micro-tension theory scalp tightness as inflammation amplifier
If DHT is the same molecule on every scalp, the divergence has to live somewhere downstream. The leading mechanical hypothesis says it lives in the fascia. Your galea aponeurotica is a tough, relatively inelastic fibrous sheet draped over the crown of the skull, anchored anteriorly by the frontalis and posteriorly by the occipitalis. The sides and back of your scalp sit over loose, mobile tissue. The top sits over the galea. Map the Hamilton-Norwood progression onto a skull and the receding frontotemporal corners and thinning vertex line up with the regions of highest resting tension on that fascial sheet.
Anyone reading older content claiming scalp tension hair loss is either fully proven or fully discredited has read content that predates the 2024 Carvalho RCT, and the answer in 2026 sits in the middle: theory plausible, botox failed, scalp massage marginal but defensible.
That observation is not new, but the formal mechanistic argument is recent. English published a finite-element-style hypothesis paper proposing that chronic galeal tension drives site-specific mechanotransduction, low-grade inflammation, perifollicular fibrosis, calvarial calcification, and eventual follicle miniaturization in exactly the AGA pattern English RS Jr. Med Hypotheses. 2018 English 2018. An older gravitational-tension hypothesis from Ustuner pointed in the same direction a few years earlier Ustuner ET. Plast Reconstr Surg Glob Open. 2013 Ustuner 2013. Neither paper proves the model. Both make the same prediction: pattern hair loss is partly a fascial problem.
Why mechanical stress and androgens converge
The bridge between this hypothesis and the DHT paradox is mechanotransduction. Dermal papilla cells, like most fibroblast-lineage cells, sense stretch through the YAP/TAZ pathway and the cytoskeleton. When skin and follicle cells are held under sustained tension in vitro, they upregulate TGF-beta and DKK-1 secretion. That is the same anagen-suppressive secretome that balding-scalp dermal papilla cells release in response to DHT. Two inputs (mechanical load and androgen signalling) feeding into one downstream cascade. On a tense scalp, the two amplify each other. On a loose scalp, neither input is loud enough to flip the follicle into catagen.
The inflammatory marker most often cited in this loop is prostaglandin D2. Garza and colleagues showed PGD2 levels roughly threefold higher in bald scalp than haired scalp, and transgenic mice overexpressing the upstream COX enzyme K14-Ptgs2 develop an AGA-like phenotype Garza LA et al. Sci Transl Med. 2012 Garza Cotsarelis 2012. PGD2 is elevated by both mechanical stress and androgen signalling, which is why it is a tidy candidate node. Honesty check. Setipiprant, a CRTH2 / PGD2 receptor antagonist developed by Allergan and later AbbVie, ran a Phase 2a trial in AGA and failed. Scalp tissue drug levels were achieved, the primary efficacy endpoint was not met, and the program was shelved Setipiprant Phase 2a AGA PMC8526366. PGD2 is probably a marker of the inflamed environment, not the lever that pulls miniaturization.
What the human evidence actually shows
The most-cited human data point for the tension model is Koyama's standardized scalp massage study. Nine men performed four minutes per day of a standardized scalp massage for 24 weeks. Hair shafts thickened measurably, and parallel in vitro work on dermal papilla cells under cyclic stretch showed upregulation of NOGGIN, BMP4 and SMAD4 with downregulation of IL-6 Koyama T et al. Eplasty. 2016 Koyama 2016. The biology is coherent with the hypothesis. The trial is N=9, single-arm, no control group, and reports a thickness signal rather than a regrowth signal. Hypothesis-supportive, not confirmatory. Treat it as a reason to try, not a reason to expect.
Botulinum toxin was the cleaner test, because injecting frontalis and occipitalis directly slackens the galea. Early uncontrolled and open-label series in the Freund and Schiestl tradition reported AGA improvement, and the scalp-tension framing rode that signal for roughly a decade. The 2024 triple-blind randomized controlled trial by Carvalho and colleagues was the first properly controlled test and found no benefit on AGA, with terminal hair density numerically decreasing in the botox arm Carvalho RAS et al. JAAD. 2024 Carvalho 2024. The physiological idea that lowering galeal tone matters is not refuted by that trial, but the specific clinical claim that botox treats scalp tension hair loss is.
Where does that leave the model. Mainstream dermatology files it as interesting and unproven. The American Academy of Dermatology guidelines do not list mechanical-tension interventions, and finasteride plus minoxidil remain the evidence-graded backbone. The micro-tension theory is best read as a contrarian frame with partial support: a coherent anatomical map, a plausible mechanotransduction pathway, one small positive massage trial, one large negative botox trial, and a failed PGD2 antagonist that narrows the inflammatory story. The practical residue is narrow but real. Daily scalp massage hair growth protocols cost nothing, carry essentially no downside, and have one supportive small trial plus a defensible mechanism behind them. That is the entire honest case for scalp massage benefits in AGA. Use it as an adjunct, and let the scalp massage benefits sit alongside the Tier 1 stack rather than replace it.
Hair regrowth T1 to T4
What actually works for hair regrowth the evidence tier
Most of the noise around hair regrowth is marketing layered over four or five molecules that actually move the needle. Here is the honest tier ranking for androgenetic alopecia (AGA), strongest evidence first. If you are asking how to regrow hair and want to skip the supplement aisle, this is the shortlist. The same ranking answers what people are looking for when they search for the best vitamins for hair growth: in almost every case, the strongest molecule for AGA hair regrowth is not a vitamin at all.
Tier 1: strongest evidence
Tier 2: real effect, smaller or more recent
Tier 3: adjuncts with positive RCT signal, smaller magnitude
Tier 4: PRP, the honest current read
Tier 1: strongest evidence
Oral finasteride and dutasteride. Both are 5-alpha reductase inhibitors that block conversion of testosterone to DHT. Dutasteride hits both type I and type II isoenzymes; finasteride hits type II only. Olsen 2006 reported dutasteride 0.5mg/day suppresses serum DHT by roughly 90 to 94 percent at 24 weeks, versus around 70 percent for finasteride 1mg/day Olsen EA et al. JAAD 2006 Olsen 2006. Decades of large-cohort data sit behind both drugs. The side effect profile is real: sexual dysfunction is reported in roughly 2 to 15 percent depending on the study, and post-finasteride syndrome remains controversial but documented in the literature. For AGA, this is still best-in-class.
Tier 1: strongest evidence
Topical minoxidil at 5 percent for men and 2 to 5 percent for women is the workhorse non-hormonal option. The mechanism is multi-pronged: ATP-sensitive potassium channel opening, growth-factor release from adipose-derived stem cells, and prolongation of the anagen growth phase Messenger AG, Rundegren J. Br J Dermatol 2004 Messenger 2004. The catch: minoxidil is a prodrug. It must be sulfated to minoxidil sulfate by follicular sulfotransferase to be active, and Glysman 2020 found that around 40 percent of non-responders carry low follicular SULT activity Glysman et al. 2020 Glysman 2020. Roughly 60 percent of users respond meaningfully. Topical minoxidil remains the default starting point for anyone unwilling to take a systemic drug.
Tier 1: strongest evidence
Microneedling for hair loss combined with minoxidil is the most underused Tier 1 move. Dhurat 2013 randomized 100 men to weekly microneedling plus 5 percent minoxidil twice daily, versus minoxidil alone, for 12 weeks. The combination added 91.4 hairs/cm-squared versus 22.2 in the minoxidil-only arm, and 82 percent of the combo group reported greater than 50 percent improvement compared with 4.5 percent for monotherapy Dhurat R et al. Int J Trichology 2013 Dhurat 2013. A 2025 meta-analysis replicated the direction and magnitude. Use 1.5mm depth, once weekly, applied before the evening minoxidil dose. Microneedling for hair loss on its own (without minoxidil layered on top) has weaker evidence and is not the recommended protocol.
Tier 2: real effect, smaller or more recent
Low dose oral minoxidil (LDOM) has gone mainstream. A 2024 meta-analysis pooled 17 single-arm and 10 randomized studies (n=2,933) across 0.25 to 5mg/day and reported equivalent or superior outcomes to topical on several endpoints LDOM meta-analysis 2024 PMC10806356. Hypertrichosis runs around 15 percent; fluid retention is 1.3 to 10 percent. The 2024 JAAD expert consensus formally legitimized off-label use JAAD Expert Consensus 2024 JAAD 2024. Note: oral minoxidil is not FDA-approved for AGA, but it is now standard practice in dermatology. The low dose oral minoxidil shift between 2023 and 2025 is the single biggest practical change in AGA prescribing of the last decade.
Tier 2: real effect, smaller or more recent
Topical finasteride 0.25 percent spray. Piraccini 2022 ran a Phase 3 RCT showing comparable efficacy to oral finasteride, with scalp DHT down 50 to 70 percent and serum DHT down only 25 to 50 percent (versus over 90 percent with oral) Piraccini BM et al. JEADV 2022 Piraccini 2022. Approved in the EU. The FDA has open safety questions as of June 2025.
Tier 2: real effect, smaller or more recent
Rosemary oil hair growth claims sit on Panahi 2015, a 6-month RCT (n=100) showing 5 percent rosemary oil non-inferior to 2 percent minoxidil Panahi Y et al. Skinmed. 2015 Panahi 2015. Honest framing: rosemary oil works mildly and is closer to a 2 percent minoxidil substitute, not a 5 percent one. Proposed mechanisms include microcapillary perfusion, anti-inflammatory effects, and possible mild 5-alpha reductase inhibition.
Tier 2: real effect, smaller or more recent
Saw palmetto at 320mg/day oral. Governa 2020 pooled 10 trials (n=502) and reported around 30 percent serum DHT reduction at 6 months and 60 percent of users reporting overall hair-quality improvement Governa P et al. 2020 Governa 2020. Real, but milder than finasteride.
Tier 3: adjuncts with positive RCT signal, smaller magnitude
Low-level laser therapy at 650 to 680nm. A 2019 meta-analysis reported a standardized mean difference of 1.32 for hair density, with follow-ups confirming the direction Liu KH et al. 2019 PMID 30706177. FDA-cleared devices exist for both sexes. Red light therapy hair growth is modest, best deployed as adjunct rather than monotherapy.
Tier 3: adjuncts with positive RCT signal, smaller magnitude
Topical melatonin 0.1 percent. Fischer 2004 (n=40 women, 6 months) showed increased anagen rate Fischer TW et al. Br J Dermatol 2004 Fischer 2004. An open-label men's study (n=35) showed 40 percent density gain at 6 months, but uncontrolled. Moderate evidence in women's diffuse alopecia, weaker in AGA.
Tier 4: PRP, the honest current read
PRP for hair loss needs an honest answer. The 2025 Khattab meta-analysis pooled 43 RCTs (n=1,877) and concluded that activated platelet-rich plasma beats placebo, shows non-significant differences versus minoxidil, and that PRP plus minoxidil outperforms either alone Khattab F et al. Dermatol Ther. 2025 Khattab 2025. Heterogeneous preparation protocols remain the field's biggest problem. The takeaway: PRP for hair loss is real, but it is not better than minoxidil on its own. The combination is the strongest move if you are paying for the procedure.
Hair regrowth arrivals
Status board- CLA-5Clascoterone 5% (Breezula)Topical anti-androgen, no systemic blockadeOn trackFiling early 2027
Both Phase 3 trials are complete across 1,465 men at 51 centres. The 12-month data read out in April 2026: a 2.39x improvement in target-area hair count for men who stayed on it the full year, and no significant systemic hormonal effects over 12 months.
- How it works
- Blocks the androgen receptor in the scalp itself, then breaks down into an inactive metabolite before it reaches the bloodstream. The same molecule is already sold as Winlevi for acne, so its safety in humans is well mapped.
- What it would mean
- This is the one that matters most for anyone who wants finasteride's effect without finasteride's reputation. The whole promise is local action: hitting the receptor at the scalp instead of lowering DHT throughout the body, which is where the sexual side-effect fears come from.
- What has to happen next
- The filing itself. Cosmo says the US submission is planned for early 2027, which was a slip from the 2026 expectation. Add roughly a year of review after that.
- KX-826PyrilutamideTopical androgen-receptor antagonistOn trackChina NDA 2026
Announced in March 2026 as meeting its Phase 3 primary endpoint in 666 patients. A separate 52-week safety study reported 46% of users gaining at least 10 hairs per square centimetre, with no drug-related sexual dysfunction.
- How it works
- Same broad idea as clascoterone: block the androgen receptor at the scalp rather than suppressing DHT body-wide.
- What it would mean
- If it holds, this becomes the closest any new hair-loss drug is to an actual approval anywhere in the world. The catch is jurisdiction. A China approval does not put it in a Western pharmacy, and it took a failed Phase 3 in 2023 to get here.
- What has to happen next
- The NMPA submission, and independent verification. The result is company-announced and no trial registry currently reflects it, so treat the numbers as provisional until published.
- PP405PP405Wakes dormant follicles by metabolic switchDelayedLate-stage not yet registered
Phase 2 is complete. In the subgroup with more advanced loss, 31% gained more than 20% hair density against 0% on placebo, with no detectable systemic absorption. That result is now 14 months old and nothing has been added to it.
- How it works
- Forces follicle stem cells off oxidative phosphorylation and back into glycolysis. That metabolic switch appears to wake follicles that have gone dormant, rather than fighting hormones at all. It is the most genuinely novel idea in the field.
- What it would mean
- A drug that reactivates sleeping follicles would work on a different axis from everything currently sold, which means it could stack with them rather than replace them. Dormant is also not dead, so it would only help where follicles still exist.
- What has to happen next
- A registered late-stage trial. The company said late-stage studies would start in 2026 and, with four months left, nothing appears in any registry. Funding is not the obstacle: they raised 120 million dollars in October 2025.
- GT-29GT20029Topical PROTAC androgen-receptor degraderOn trackPhase 3 pending
Phase 2 complete in 180 men. All four dose arms significantly increased hair count at 12 weeks. Side effects matched placebo, with no sexual dysfunction reported.
- How it works
- Rather than blocking the androgen receptor, it tags the receptor for destruction and the cell disposes of it. Fewer receptors means less for DHT to act on. This is the first time this drug-design approach has reached Phase 2 in hair loss.
- What it would mean
- Interesting mainly as a proof that receptor destruction works topically. The absolute gains were modest, so this looks like a clean adjunct rather than a headline treatment.
- What has to happen next
- A registered Phase 3. Nothing is on the registry yet.
- ABS-201ABS-201AI-designed antibody, first systemic entrantOn trackData 2028
First-in-human Phase 1/2 recruiting now, 227 people, given by injection rather than applied to the scalp. Open to both men and women.
- How it works
- An antibody designed with machine learning, delivered systemically. It is the first genuinely new mechanism class to enter pattern hair loss in years, and the first serious attempt to treat it as a whole-body target rather than a scalp one.
- What it would mean
- Worth watching precisely because it does not look like anything else on this board. Including women in a first-in-human study also matters, since female pattern loss is routinely an afterthought in this pipeline.
- What has to happen next
- Safety first. It is a first-in-human study and primary completion is not until July 2028, so this is a long horizon, not a near-term option.
- ET-02ET-02Stem-cell reactivation, mechanism undisclosedDelayedNo registered trial
One striking press release in January 2025 reported roughly six times more hair growth than placebo at five weeks in 24 people. Nothing has followed.
- How it works
- Publicly thin. The company frames it as stem-cell reactivation, possibly mitochondrial, and has not published a mechanism paper.
- What it would mean
- Treat the six-fold number with care. It came from 24 people over five weeks, and short trials in hair loss routinely produce numbers that do not survive longer study.
- What has to happen next
- Any registered trial at all. The widely-reported 150-patient Phase 2 does not appear in any registry, and the company's registered pipeline is entirely cosmetic anti-wrinkle work.
- VM-GTHair cloningGrowing new follicles from reprogrammed cellsDelayedNot this decade
Still preclinical everywhere. No company has produced a working human follicle-neogenesis product, and none has a registered efficacy trial.
- How it works
- Reprogram cells into follicle-forming cells and grow entirely new follicles, rather than rescuing existing ones. It is the only approach that would help someone who has already lost the follicles.
- What it would mean
- This is the thing people actually want, and it is the furthest away. Anyone selling hair cloning today is selling something else.
- What has to happen next
- A first-in-human trial. Realistically this remains three to five years from any marketable product, and that estimate has been three to five years away for a while.
Hair regrowth Pipeline
Emerging treatments worth watching
Investigational status (as of 2026): PP405, ET-02, GT20029, rezpegaldesleukin, SCUBE3, JW0061, dNovo and Stemson are not FDA-approved for any indication. Clascoterone (Winlevi) is FDA-approved for acne (2020), not yet for androgenetic alopecia. JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) are FDA-approved for alopecia areata, not pattern hair loss. Pyrilutamide (KX-826) is not FDA-approved. None of the entries below should be acted on without a clinician relationship and current trial-registry confirmation; what follows is a research-watch map, not a treatment recommendation.
The hair regrowth pipeline between 2024 and 2026 is the most active it has been in two decades. Most of what follows is not yet prescribable. The point of this section is to separate late-stage assets with real readouts from preclinical promise that gets oversold in the lay press. Tier order reflects regulatory proximity, not effect size.
Late-stage or already approved
Clascoterone (CB-03-01, brand name Breezula for scalp). A topical androgen-receptor antagonist already FDA-approved at 1 percent as Winlevi for acne in 2020 Winlevi FDA approval 2020 FDA 2020. The scalp formulation ran two pivotal Phase 3 trials, SCALP-1 and SCALP-2, with combined enrollment of 1,465 men, and the 5 percent concentration met its primary endpoint of change in target-area hair count at 6 months Cosmo Pharmaceuticals SCALP trials NCT05126485. Regulatory submission for androgenetic alopecia is expected after the 12-month safety follow-up reads out in spring 2026. Of every drug in this section, clascoterone is the strongest near-term prospect for a topical anti-androgen that does not depend on systemic 5-alpha-reductase blockade.
Late-stage or already approved
JAK inhibitors for alopecia areata. This is an important distinction patients routinely get wrong: JAK inhibitors are approved for autoimmune alopecia areata, not for AGA. Three approvals landed in two years. Baricitinib (Olumiant) on June 13, 2022. Ritlecitinib (Litfulo) on June 23, 2023, with a label down to age 12. Deuruxolitinib (Leqselvi) on July 25, 2024 FDA JAK inhibitor approvals 2022-2024 FDA 2022-2024. These drugs suppress the immune attack on the follicle. The mechanism is wrong for pattern hair loss, so do not let marketing copy elide the two indications.
Active Phase 2 or Phase 3
PP405 from Pelage Pharmaceuticals is the asset generating the most legitimate scientific interest. It is a topical mitochondrial pyruvate carrier inhibitor that forces follicle stem cells out of oxidative phosphorylation and back into glycolysis, which appears to wake up dormant hair follicles that have entered prolonged telogen. The Phase 2a trial enrolled 78 participants on 0.05 percent topical once daily for 4 weeks with follow-up to 12 weeks Pelage PP405 Phase 2a NCT06393452 NCT06393452. Precision matters on the headline result: 31 percent of PP405-treated patients in the higher-baseline-loss subgroup achieved greater than 20 percent increase in hair density versus 0 percent on placebo at week 8, which is 4 weeks post-treatment. No detectable systemic absorption was reported. Phase 3 is expected in 2026. The PP405 hair loss data is the cleanest current example of stem cells hair loss biology translating from bench to clinic, and it sits at the centre of the broader effort to wake up dormant hair follicles through metabolic rather than hormonal pathways.
Active Phase 2 or Phase 3
GT20029 from Kintor Pharmaceutical is the first topical PROTAC androgen-receptor degrader to reach Phase 2. The 180-patient China trial showed 0.5 percent once daily added 6.69 hairs per cm-squared over placebo at 12 weeks (P less than 0.05), and 1 percent twice weekly added 7.36 hairs per cm-squared over placebo Kintor GT20029 Phase 2 2023 Kintor 2023. Adverse-event rates matched placebo with no sexual side effects reported. Absolute effect is modest, but the safety profile is clean. Phase 3 in China and Phase 2 in the United States are underway.
Active Phase 2 or Phase 3
ET-02 from Eirion Therapeutics is the wildcard. The Phase 1 readout in January 2025 (n=24) reported a 6-fold increase in non-vellus hair count at 5 weeks with the 5 percent solution, outperforming 4 months of minoxidil in an exploratory head-to-head arm Eirion ET-02 Phase 1 2025 Eirion 2025. Mechanism is publicly thin and framed around stem-cell reactivation, possibly mitochondrial. A 6-month Phase 2 with roughly 150 patients launched later in 2025. The compound reportedly affects pigmentation as well as growth. Early but striking, and worth tracking.
Active Phase 2 or Phase 3
Rezpegaldesleukin from Nektar is a Treg-biasing IL-2 again for alopecia areata, not AGA. Phase 2b REZOLVE-AA met its endpoints and Phase 3 begins 2026 Nektar REZOLVE-AA 2025 Nektar 2025. It expands the autoimmune-alopecia toolbox alongside the JAK class with a potentially better safety profile.
Early stage, cell therapy, and contested
Verteporfin, a YAP inhibitor FDA-approved in 2000 for macular degeneration, gained hair interest from the Plikus and Longaker labs. The Mascharak 2021 paper in Science showed it blocks fibroblast-to-myofibroblast transition and regenerates follicles and sweat glands in porcine wounds Mascharak S et al. Science 2021 Mascharak 2021. Subsequent hair-transplant adjunct work remains small-N and unblinded. It is not an AGA drug. The credible promise is donor-site preservation and scar regeneration around grafts.
Early stage, cell therapy, and contested
SCUBE3, a dermal-papilla-secreted signaling protein, was reported by the Plikus lab in 2022 to activate hair follicle stem cells in mouse and human scalp xenografts Gay D et al. Dev Cell 2022 Gay 2022. A patent was filed. No human trial has started.
Early stage, cell therapy, and contested
Shiseido S-DSC, also called RCH-01, is autologous cultured dermal sheath cup cell injection therapy and the only true cell therapy actually launched. Toho University Ohashi Hospital began offering it as a paid out-of-pocket treatment in Japan in July 2024 Shiseido S-DSC Toho 2024 Shiseido 2024. The 2023 Phase 3-equivalent data was positive but density gains were modest, and the Replicel-Shiseido license dispute is ongoing. A real effect, a small one.
Early stage, cell therapy, and contested
Stemson Therapeutics, dNovo, and JW Pharmaceutical's JW0061 (a Wnt agonist) are all preclinical or earliest-clinical. True hair cloning, meaning de novo follicle neogenesis from induced pluripotent or reprogrammed cells, remains 3 to 5 years from a marketable product. Anyone selling hair cloning today is selling something else.
Early stage, cell therapy, and contested
Pyrilutamide (KX-826), also from Kintor, is a topical AR antagonist that failed its primary endpoint in the November 2023 China Phase 3 readout. An extended 52-week long-term Phase 3 reported the primary endpoint met in March 2025, but data quality is contested by independent reviewers. Status is ambiguous. Even on a charitable read, the effect looks weaker than clascoterone.
Early stage, cell therapy, and contested
One adjacent category deserves a one-line warning. Exosomes hair growth products and hair growth peptides (GHK-Cu and copper tripeptide variants) are sold aggressively in clinics and direct-to-consumer, but the supporting trials are typically small, unblinded, and industry-funded. Treat the marketing as preclinical until a properly powered independent trial publishes. The same caution applies to most hair growth peptides sold as topicals or injectables outside research settings.
You can keep reading. Or you can see what this looks like in real bodies.
Same mechanism you just read about. Different bodies. Same outcome.
Hair regrowth Failed
Stalled and failed the cautionary tale
The hair-loss field is a graveyard of 'this might revolutionize' press releases that quietly fade once properly powered trials report. Most consumer hair content describes the hopeful Phase 1 readout and never updates when Phase 2 or Phase 3 fails. This section names the specific failures so you do not waste money chasing yesterday's hype, and so the difference between a plausible mechanism and a working drug is visible on the page.
Setipiprant: the PGD2 antagonist that did not translate
Setipiprant is an oral CRTH2 receptor antagonist licensed by Allergan to test the prostaglandin D2 hypothesis advanced by Garza and Cotsarelis in 2012, which observed elevated PGD2 in balding scalp tissue. The Phase 2a trial reported in 2018 confirmed adequate scalp tissue drug levels (the molecule reached the target) but failed its primary efficacy endpoint for hair growth in androgenetic alopecia Setipiprant Phase 2a 2018 PMC8526366. The program was shelved. The PGD2 hypothesis itself remains scientifically defensible, but the receptor antagonist approach did not produce a clinical signal.
Botulinum toxin for AGA: downgraded by a real RCT
Earlier uncontrolled and small open-label studies suggested intramuscular scalp botulinum toxin reduced perifollicular tension and helped androgenetic alopecia. The 2024 JAAD triple-blind randomized controlled trial by Carvalho and colleagues was the first properly controlled investigation, and it found no benefit Carvalho RAS et al. JAAD 2024 Carvalho 2024. Terminal hair density actually decreased in the botulinum arm. The Freund and Schiestl scalp-tension hypothesis is still physiologically interesting, but botulinum toxin specifically does not work clinically for AGA. If you encounter older content recommending botox injections for hair loss, that content is pre-2024 and is now superseded by a properly powered trial.
Pyrilutamide (KX-826): contested signal
Pyrilutamide, also known as KX-826, is a topical androgen receptor antagonist developed by Kintor. The Phase 3 readout in China in November 2023 failed its primary endpoint. An extended 52-week long-term Phase 3 reported in March 2025 claimed the primary endpoint was met, but data quality and trial conduct have been contested by independent reviewers. The honest status is ambiguous. If pyrilutamide ultimately works, the effect size appears smaller than clascoterone, which has the cleaner regulatory and trial record.
PC-KUS: the pseudocatalase that never replicated
PC-KUS is a topical pseudocatalase formulation popularized by the Schallreuter group, who in 2013 reported pigment restoration in vitiligo and grey hair across a cohort of 2,411 vitiligo patients Schallreuter KU et al. 2013 Schallreuter 2013. The underlying chemistry (accelerating breakdown of accumulated hydrogen peroxide) is mechanistically reasonable and connects to the Wood 2009 line of follicular oxidative biology. The problem is reproducibility. PC-KUS has not been independently replicated at scale outside the original group, has no FDA approval, and remains clinic-only over a decade later.
'Stem cell' topical serums without actual cells
A persistent marketing trend labels cosmetic serums as 'stem cell' formulations when the contents are growth-factor extracts or conditioned media, with no live cells and no demonstrated mechanism for hair regrowth at the topical concentrations used. These products are distinct from genuine cell therapy programs such as Shiseido S-DSC or Stemson, which involve actual cultured dermal sheath cells. The marketing borrowing of the phrase 'stem cell' does not transfer the biology.
Most exosome hair clinics
Exosome injection clinics expanded aggressively through 2024 and 2025, charging premium prices for unstandardized preparations sourced variably from placental, adipose, or even plant material. A 2025 systematic review identified only two randomized controlled trials in the published literature, with heterogeneous sources and inconsistent outcomes Dovepress CCID 2025 PMID 40955427. There is no FDA-approved exosome product for hair loss, and the FDA has actively warned against unapproved exosome injectables. The exosomes hair growth category is, in 2026, premium pricing without published Phase 3 data.
A reasonable theory is not the same as a working drug.
The pattern
A theory survives clinically when the receptor antagonist or downstream intervention also works, not just when the upstream observation is reproducible. The PGD2 theory is reasonable and setipiprant failed. The mechanical-tension theory is reasonable and botulinum toxin failed. The pseudocatalase chemistry is reasonable and the trial failed to replicate. The pattern is straightforward: be slow to act on press releases, be patient for properly powered RCTs, and assume any treatment without a published controlled trial is closer to marketing than to medicine.
Hair regrowth Inflated
Marketed but inflated compound-by-compound honest verdicts
The hair-product industry is meaningfully larger than the evidence supporting it. Most over-the-counter shampoos, serums, gummies, and tonics sit somewhere between 'in vitro mechanism with no human topical trial' and 'modest cosmetic effect oversold as regrowth.' The point of this section is to evaluate compounds, not brands. The same company can sell a product with weak evidence in one line and a product with legitimate biology in another. Verdicts here are at the compound and formulation level.
Plantur 39: a dual verdict, same brand, different lines
Plantur 39 is the cleanest example of why brand-level reviews mislead. The brand sells two largely independent product families with very different evidence profiles, and a fair plantur 39 review has to grade them separately rather than collapsing both into a single thumbs-up or thumbs-down.
The Phyto-Caffeine line (Shampoo and Tonic). The active stack is caffeine plus niacinamide plus zinc PCA, with soy phytoestrogens added in the 39 (women over 40) version. The caffeine evidence trail starts with Fischer 2007 Fischer TW et al. Int J Dermatol. 2007 Fischer 2007, an ex vivo organ-culture study on 14 vertex biopsies showing caffeine reversed testosterone-suppressed follicle elongation. Fischer 2014 Fischer TW et al. Br J Dermatol. 2014 Fischer 2014 extended the mechanism by showing modulation of TGF-beta2 and IGF-1 in follicle culture. The often-cited Dhurat 2017 caffeine 0.2 percent liquid versus minoxidil 5 percent non-inferiority trial is industry-sponsored and methodologically thin. The well-known '120-second penetration' claim traces to Otberg 2007 follicle-shaft penetration data, which is real in principle, but rinse-off shampoo contact time and dose-on-target at the dermal papilla are the weak link. The honest answer to does plantur 39 work for the caffeine line is: mechanistically plausible, modestly supported in ex vivo and culture work, and inflated relative to in vivo human regrowth evidence. Niacinamide is a legitimate cosmetic barrier ingredient with no regrowth claim that survives scrutiny. Zinc PCA inhibits 5-alpha-reductase in vitro Stamatiadis 1988 Stamatiadis 1988 but there is no scalp-DHT-reduction RCT at caffeine shampoo concentrations. Soy isoflavones and genistein inhibit 5-alpha-reductase in vitro with no human topical AGA RCT. Biotin (carried in the Plantur 21 sister product) has zero RCT evidence in non-deficient users Patel et al. JCAD. 2024 Patel 2024. Verdict on the caffeine line: partially supported mechanistically, inflated relative to human in vivo evidence.
The Anti-Grey Effect line. This is a separate product family with different chemistry and a different verdict. The Anti-Grey Effect Shampoo INCI declares 6-hydroxyindole, HC Blue No. 2, and 2-Amino-6-Chloro-4-Nitrophenol, which are semi-permanent direct dyes; the front-of-pack '5,6-DHI' branding refers to the indole category, not a literal single ingredient. The Anti-Grey Effect Colouring Conditioner SKU declares 5,6-DHI more prominently and uses a leave-on contact time of roughly 10 minutes, which is a closer-to-pure DHI delivery vehicle than the rinse-off shampoo. Functionally the system is layered: an HC-dye top note that fades over 6 to 10 washes, plus an indole polymer base note that builds visibly over 2 to 4 weeks and is wash-resistant but degrades under UV and chlorine. Verdict on the Anti-Grey line: legitimately gentler chemistry than oxidative permanent dye for grey coverage, with a different evidence profile from the caffeine line under the same brand name. A buyer-level walkthrough of the dye chemistry sits in a later H2.
Nutraceuticals: the 'real but small' tier
Nutrafol. The 6-month and 12-month industry-sponsored RCTs show modest density gains at the trichoscopy level. By nutraceutical standards this is best-in-category, but funder bias is unaddressed, the absolute effect size is modest, and the comparator is not minoxidil or finasteride. An honest nutrafol review: real-but-small, oversold relative to its measured effect size, and inferior to Tier 1 pharmacological options.
Viviscal. The marine-extract complex (AminoMar) has trial data going back two decades, but the 2025 network meta-analysis of nutraceutical and pharmacological AGA interventions found no statistically significant density advantage at 12 or 24 weeks. Verdict on a fair viviscal review: inflated.
Single-ingredient OTC claims
Biotin for hair (in non-deficient users). Patel 2017 Patel D et al. Skin Appendage Disord. 2017 Patel 2017 and Patel 2024 systematic reviews both report zero RCT evidence for biotin for hair regrowth in people without a measurable deficiency. Frank biotin deficiency is rare outside biotinidase deficiency, sustained raw-egg-white intake, valproate, or isotretinoin therapy. Biotin also interferes with TSH and troponin lab assays at common supplement doses, which is a clinical liability rather than a regrowth benefit. Verdict: inflated.
Hair vitamins and gummies (SugarBearHair and similar). The same biotin-complex evidence gap, repackaged with sugar and modest doses of B-complex vitamins. There is no RCT supporting these hair vitamins as monotherapy for AGA or telogen effluvium in non-deficient users. The same applies to most products marketed as vitamins for hair loss: the category exists because the search volume exists, not because the evidence does. Verdict: inflated.
Collagen peptides. The Verisol bioactive collagen peptide protocol at 2.5g per day for 16 weeks shows shaft-thickness gains in one RCT (n=44 women), with newer studies replicating cosmetic shaft improvements. The mechanism is shaft-quality and dermal collagen support, not follicle regrowth. Verdict: modest, real, mostly cosmetic shaft quality. Defensible for shaft thickness, inflated when sold as a regrowth agent.
Onion juice. Sharquie 2002 Sharquie KE, Al-Obaidi HK. J Dermatol. 2002 Sharquie 2002 reported 86.9 percent regrowth at 6 weeks in alopecia areata (n=23), unrandomized and unblinded, in an autoimmune patchy condition mechanistically distinct from androgenetic alopecia. The trial has not been replicated in 23 years. Verdict: folk curiosity, not an evidence base for AGA.
Castor oil. No human RCT for hair growth at all. The ricinoleic acid to PTGDS-inhibition mechanism is in vitro only and has not been demonstrated to translate to scalp delivery or follicle outcomes. Verdict: inflated.
Rice water. No scalp-penetration data, no RCT. The visible 'thickening' effect is reduced breakage and surface conditioning from inositol and starches, which improves how hair looks without growing follicles. Verdict: inflated as a regrowth claim, defensible only as a styling and breakage-reduction rinse.
The pattern
Evaluated by compound rather than brand, most over-the-counter hair products land in two buckets: modest cosmetic effect (collagen peptides, niacinamide, conditioning rinses) or in vitro mechanism without a human topical RCT (zinc PCA, genistein, castor oil, rice water). That does not make any of them useless on their own terms. It does make them wrong as monotherapy substitutes for the Tier 1 evidence stack of finasteride, minoxidil, and microneedling-plus-minoxidil covered in the previous section. The BellyProof rule for hair regrowth spending: pay for what has an RCT, treat everything else as adjacent, and never let a marketing page teach you what your follicle responds to.
Why your hair greys the modern picture
Greying is not a slow leak of pigment, and it is not a tank running dry. The follicle is a stem-cell compartment with a maintenance job to do every cycle, and grey hair is what happens when that maintenance fails. The pigment-producing cells (melanocytes) are renewed each hair cycle from a small pool of melanocyte stem cells (McSCs) that sit in the upper follicle. When that pool stops cycling correctly, the new hair shaft grows in unpigmented. Around that core failure sits a layer of oxidative stress biology, a layer of neural and hormonal stress signalling, and a strong genetic baseline. Greying is the visible output of all four.
The melanocyte stem cell story: stuck, not lost
The most important mechanistic shift in the last few years comes from the Sun et al. 2023 paper in Nature Sun Q et al. Nature 2023 Sun 2023. The authors showed McSCs are not a static reserve. They physically shuttle between the bulge and the hair germ regions of the follicle across each hair cycle, dedifferentiating between a quieter progenitor state and an active transit-amplifying cell (TAC) state that matures into pigment-producing melanocytes. That plasticity is what keeps a follicle pigmented over decades.
With age, and with forced or repeated cycling, roughly half of these McSCs get stuck in the bulge. They lose the ability to shuttle, lose their plasticity, and can no longer mature into melanocytes when the follicle calls for pigment. The hair then grows in white. That distinction is what keeps repigmentation biologically plausible at all, even if no drug yet exploits it.
Hydrogen peroxide and the catalase decline
ten percent catalase, per decade after twenty
The oxidative stress angle is older and well documented. Wood 2009 in FASEB J Wood JM et al. FASEB J 2009 Wood 2009 reported massive epidermal hydrogen peroxide accumulation in grey hair follicles, with reduced expression of catalase and methionine sulfoxide reductase A and B (the two enzyme systems that would normally neutralise peroxide and repair the oxidative damage it causes to tyrosinase). Shi 2014 in PLoS One Shi Y et al. PLoS One 2014 Shi 2014 confirmed reduced catalase and increased H2O2 in grey versus pigmented follicles in a separate cohort.
Trueb 2021 framed the systemic version of this: catalase activity falls roughly ten percent per decade after age twenty Trueb RM. Int J Cosmet Sci 2021 Trueb 2021. The biology is real. The treatment translation is not. Catalase is a 240 kDa tetrameric protein, which means oral catalase pills are digested to amino acids in the stomach and topical catalase does not penetrate intact follicle epithelium. The peroxide story explains a real piece of why greying happens. It does not, in 2026, give you a working drug.
Stress, sympathetic nerves, and the bounded reversal window
The Rosenberg and Picard 2021 paper in eLife took a clever approach: high-resolution proteomic mapping along single hair shafts, correlated to time-stamped life events Rosenberg AM et al. eLife 2021 Rosenberg 2021. Hairs greyed during periods of psychological stress, and in some subjects repigmented along the same shaft when stress dropped. The reversal effect clustered in middle-aged subjects near their personal greying threshold, not in already-fully-grey older subjects. The work is quantitatively rigorous, but the sample is small and observational. It defines a bounded reversibility window, not a general claim that stress reduction undoes grey hair.
The mechanism behind stress and grey hair: Zhang et al. 2020 in Nature Zhang B et al. Nature 2020 Zhang 2020 showed norepinephrine released from hyperactivated sympathetic nerves drives McSCs into rapid differentiation and depletion in mouse models. The signal that translates psychological stress into stem-cell loss is sympathetic nervous system overdrive. Mice are not humans, and the human picture is more complex, but the directionality is consistent with the Rosenberg observations.
Genetics: the part you cannot prevent
75 to 90 percent heritability of greying onset
Large GWAS work has linked the IRF4 polymorphism to age of greying onset, and twin studies put heritability of greying onset age at roughly 75 to 90 percent. That is the largest single explanatory factor for premature greying causes in any individual. If both parents went grey at thirty, the oxidative and stress layers above are fine-tuning a strongly pre-set timer. Stress and grey hair interactions can pull that timer earlier and, in narrow circumstances, ease it later. They do not rewrite it.
The honest summary of why hair turns grey in 2026: McSCs get stuck rather than disappearing (Sun 2023), follicular peroxide accumulates as antioxidant enzymes decline (Wood, Shi, Trueb), sympathetic stress signalling depletes the active pool (Zhang, Rosenberg), and genetics sets the underlying schedule. What causes grey hair is a four-layer answer, not one.
The headline finding is the one that matters for how you should think about grey: most grey hair is stuck stem cells, not lost stem cells.
Grey hair arrivals
Status board- MNX-RPMinoxidil repigmentation trialFirst properly powered human trial on greyLandedCompleted Feb 2026
141 adults, placebo-controlled, twice-daily 5% topical minoxidil for 12 months, with grey scored by two blinded physicians. It finished on schedule in February 2026 and has published nothing.
- How it works
- Not designed around pigment biology at all. Minoxidil extends the growth phase of the hair cycle, and the question is whether pushing follicles through more cycling gives stalled pigment cells another chance to switch back on.
- What it would mean
- This is the most rigorous test grey hair has ever had, using a drug millions already own. If it is positive it changes the field overnight, and if it is null it closes off the most accessible hypothesis.
- What has to happen next
- Publication. Results are not posted and no paper has appeared. Trials that finish quietly and stay unpublished more often than not did not work.
- P53-SDSeno-differentiationWhy some grey is gone for goodLandedPublished Oct 2025
Published in Nature Cell Biology in October 2025 by the laboratory that founded this field. Pigment stem cells that take DNA damage are forced to mature and permanently leave the stem cell pool.
- How it works
- Damaged cells are pushed down a one-way exit by the p53 pathway. The same study found the opposite response to cancer-causing damage, where the cells stay and self-renew instead, which is how melanoma starts. Greying may be a disposal route that protects you.
- What it would mean
- This splits grey into two kinds. Some pigment cells are stalled and still present, which is what makes repigmentation thinkable. Others are gone, and no drug reaches them. Nothing tells you which kind you have.
- What has to happen next
- Human confirmation. This is mouse work under artificial DNA damage, and it has not been shown that ordinary age-related greying uses the same route.
- CS-001CS-001First drug built specifically for grey hairDelayedRegistered, not enrolling
A Phase 3 for 240 people exists on the registry, scoring greying severity at 52 weeks. Its start date passed more than a year ago with no update, and its supporting evidence has never been published.
- How it works
- Described by the sponsor as a small molecule affecting lysosomal storage and the transfer of melanin from pigment cells into the growing hair. No peer-reviewed paper supports it.
- What it would mean
- Notable only because it is the first time a drug has been developed specifically to treat grey hair rather than hair loss. That is a milestone for the category, not evidence of anything.
- What has to happen next
- Actually opening for enrolment. A registered trial that never starts is not a pipeline, and the supporting data needs to be published.
- MTORmTOR inhibitionRestarting pigment in surviving folliclesOn trackPhase 1/2 pending
In human scalp follicles grown in the lab, rapamycin increased melanin and pigment-enzyme activity. Grey follicles showed high mTOR activity compared with pigmented ones. A Phase 1/2 topical trial is registered but not yet enrolling.
- How it works
- mTOR activity appears to suppress pigmentation, so damping it lets pigment production restart. This is human tissue rather than mouse, which is unusual and makes it more relevant.
- What it would mean
- The single most instructive result on this board, because of how it failed. Repigmentation happened only in follicles that still had living pigment cells. It is direct proof that the stalled kind can be restarted and the lost kind cannot.
- What has to happen next
- A trial that actually enrols. Also worth noting rapamycin is a serious immunosuppressant systemically, so everything here depends on it staying local.
- SENOSenolyticsClearing worn-out cellsGroundedPrevention only, in mice
Widely marketed as reversing grey. The study behind the claim gave mice a senolytic drug pair before they had greyed, and it slowed the greying that followed.
- How it works
- Senolytics kill senescent cells that leak inflammatory signals into surrounding tissue. In the study, ageing follicle stem cells did carry senescence markers.
- What it would mean
- Prevention in an animal is not reversal in a person, and treating before the problem appears is not the same as treating after. Nothing here supports taking these compounds for existing grey.
- What has to happen next
- Nothing is scheduled. There is no human trial with hair pigment as an endpoint.
Can grey hair be reversed? The honest, bounded answer
The short answer in 2026: there is no proven, FDA-approved drug that repigments grey hair in the general population. The longer answer has three real pieces (a bounded reversibility window, some credible systemic redox work, and deficiency correction in specific cases) and several inflated or fraudulent ones. This section separates them.
The Rosenberg reversibility window, in human terms
Rosenberg and Picard 2021 is the strongest evidence for any kind of grey hair reversal in humans. Stress-driven greying did spontaneously reverse along single hair shafts when the stressor lifted. The honest reading: the effect was concentrated in middle-aged subjects near their personal greying threshold, the sample was small, the reversal was partial, and the window appears to close as the underlying McSC pool depletes. Useful framing for can you reverse grey hair at the right life stage. Not a license to promise anyone over fifty that meditation will undo their greys.
GlyNAC: real systemic redox, not a measured hair-pigment trial
The GlyNAC work from the Sekhar lab at Baylor is the most credible systemic anti-aging redox intervention with human RCT data. Kumar et al. 2023 Kumar P et al. J Gerontol A Biol Sci Med Sci 2023 Kumar 2023 ran a 24-week trial in older adults at 100 mg/kg/day each of glycine and N-acetylcysteine. Glutathione rose roughly 64 percent, oxidative stress markers fell, mitochondrial dysfunction improved, and several aging hallmarks moved in the right direction. Effects regressed within 12 weeks of stopping.
The catch: hair pigment was not a measured endpoint in that trial. Anyone selling GlyNAC as a supplement for grey hair is extrapolating from systemic redox to a follicle-specific outcome the trial did not measure. The honest framing: GlyNAC has real systemic anti-aging signal in small trials, the redox biology is consistent with the Wood and Shi follicle peroxide data, and a hair-pigment effect is plausible but unproven. Take it for the systemic redox case if you want; do not expect a guaranteed pigment outcome.
PC-KUS: stalled
PC-KUS is a modified pseudocatalase from the Schallreuter group, descended from the Wood 2009 peroxide work. Schallreuter 2013 reported pigment restoration in vitiligo and grey hair across 2,411 vitiligo patients using UVB-activated PC-KUS. The status in 2026: never independently reproduced at scale, no FDA approval, clinic-only distribution. Mechanistically interesting, practically stalled.
Greyverse and palmitoyl tetrapeptide-20: preliminary, manufacturer-affiliated
Palmitoyl tetrapeptide-20 (Greyverse) is an alpha-MSH analog marketed as a topical for how to reverse grey hair. Pomari 2023 Pomari E et al. Int J Trichology 2022/2023 Pomari 2023 published a small open-label study (n=15 Caucasian men) showing melanosome biogenesis stimulation and eumelanin upregulation, with one anecdotal case reported at over 90 percent conversion by month five. No randomised controlled trial exists. The study is manufacturer-affiliated. Treat as preliminary signal, not established efficacy.
Oral catalase pills: do not work
Catalase is a 240 kDa tetrameric protein. Oral catalase enters the stomach and is digested to amino acids; there is no mechanism for systemic intact delivery to the follicle. Products marketed as a 'grey hair pill' built around oral catalase have zero credible bioavailability path. The verdict on this category sits between inflated and fraudulent. The peroxide biology is real; this product class does not address it.
Deficiency correction: the one supplement story that holds up
The strongest supplement-based case for reverse grey hair naturally is the unglamorous one: correcting frank nutritional deficiencies. Case series and observational work link premature greying to B12 deficiency, iron deficiency, copper deficiency, and vitamin D insufficiency. In subjects with documented deficiency, correction can slow further greying and in some cases partially reverse recent greying. The honest vitamin for grey hair answer: get a basic blood panel first (B12, ferritin, copper, vitamin D, thyroid). If something is genuinely low, correct it; expect a real but partial effect. If everything is in range, no supplement protocol has reliable evidence for pigment recovery.
Stop hair from going grey: where the lever actually sits
The genuine levers for stop hair from going grey early, based on the mechanism layers, are: keep sympathetic stress load from chronically elevating (Zhang, Rosenberg), do not let frank deficiencies persist, and accept the IRF4-driven schedule sets the floor. Everything beyond that, in 2026, is either preliminary, stalled, or fraudulent.
The honest closing
For most adults asking can grey hair be reversed, the closest real-world solution is not a pill. It is the biomimetic dye chemistry covered in the next section, where the alternatives split into three honest tiers: true biomimetic 5,6-DHI chemistry that builds eumelanin-like pigment inside the shaft, gentler conventional oxidative dyes, and traditional PPD-based oxidative dyes. The 2026 answer to grey hair reversal is bounded yes (stress reversal near the greying threshold, deficiency correction in deficient subjects) and broad no (no drug exists). For everyone outside those narrow cases, the dye taxonomy is closer to a working solution than any supplement on the market.
The biomimetic dye honest tier Hairprint vs Plantur Anti-Grey vs PPD
Most 'natural hair dye' marketing collapses three completely different chemistries into one fuzzy category. They are not the same. Tier 1 is genuine biomimetic eumelanin chemistry that recreates the same pigment your follicle used to make. Tier 2 is gentler conventional oxidative dye, often labeled 'ammonia free hair dye' or marketed around food-grade oils, but still relying on peroxide and aromatic amines. Tier 3 is standard PPD-based oxidative dye, the box-dye and salon default. The differences matter for allergy risk, for what the chemistry does to the hair shaft, and for what the product can realistically achieve on grey hair.
Tier 1: Genuinely biomimetic
- tyrosine
- DOPA
- dopaquinone
- DHI and DHICA
- eumelanin polymer
Two products sit in this tier. Hairprint (US, formulated by green chemist John Warner) uses L-DOPA sourced from Mucuna pruriens, ferrous and manganese gluconate as catalysts, and a dilute peroxide step to oxidatively generate eumelanin in situ on the hair shaft. It is a single salon-style application of roughly 45 minutes. Plantur 39 Anti-Grey Effect takes a different route: synthesized 5,6-DHI in the Colouring Conditioner SKU, plus 6-hydroxyindole and HC dyes in the Shampoo SKU. The indoles auto-oxidize on the hair shaft over 5 to 10 washes and build a eumelanin-like polymer.
The underlying biology is the Raper-Mason pathway: tyrosine to DOPA to dopaquinone, through cyclization intermediates, to DHI and DHICA, to eumelanin polymer d'Ischia M, Napolitano A. Int J Mol Sci 2018 d'Ischia 2018. L'Oreal holds foundational patents on indole-based oxidative pigment generation. This is not a moisturizer with a 'natural' sticker. It is the same end-pigment chemistry your own melanocytes ran before they failed.
Limitations are real. Biomimetic chemistry produces eumelanin, which means brown to black hair only. There is no equivalent biomimetic pheomelanin pathway for the red and blonde end of the spectrum. Hairprint produces stronger single-application coverage. Plantur Anti-Grey builds gradually over weeks. Both photo-bleach in UV and degrade in chlorine, because eumelanin polymers are simply not UV-stable. This is a feature of the chemistry, not a manufacturing flaw.
Tier 2: Gentler conventional oxidative
This is where most of the 'natural hair dye' marketing budget goes. Examples include Simpler Hair Color (avocado-marketed), L'Oreal Excellence Creme Ammonia-Free, Garnier Olia, Clairol Natural Instincts, and Naturtint. The active chemistry is TDS (toluene-2,5-diamine sulfate) plus p-aminophenol plus couplers, with 3 percent hydrogen peroxide as developer and ethanolamine as alkalizer instead of ammonia.
Run the audit honestly. PPD free hair dye? Yes. Ammonia-free? Yes. Peroxide-free? No. Biomimetic? No. The avocado, aloe, coconut, jojoba, and meadowfoam oils on the front of the box are conditioning agents that do not participate in the coloring reaction. They sit alongside the chemistry, not inside it. Tier 2 is genuinely better tolerated by the subset of users with PPD contact dermatitis: roughly 57 percent of PPD-allergics tolerate TDS in patch testing Scheman A et al. Scheman. It still cuts the cuticle and oxidizes the cortex with peroxide. It is just gentler than ammonia-based oxidative chemistry, not gentle in absolute terms.
Tier 3: Traditional PPD-based oxidative
Standard box dyes and salon dyes. PPD or PTD, plus ammonia, plus peroxide. The highest allergy risk, the fastest and most complete coverage, the full color range including reds and blondes. PPD allergy is the leading cosmetic contact dermatitis trigger globally Mukkanna KS et al. J Asthma Allergy 2017 Mukkanna 2017. Real damage to the shaft is documented: cuticle lifting, cortex protein loss, and lipid stripping including 18-MEA depletion. This tier delivers what consumers usually mean by 'dyed hair,' at a real biological cost.
Verdict matrix
| Tier | Allergy risk | Shaft damage | Coverage speed | Color range |
|---|---|---|---|---|
| 1 Biomimetic (Hairprint, Plantur Anti-Grey) | Very low | Low | Gradual or single salon-style session | Brown to black only |
| 2 Gentler oxidative (ammonia-free, oil-marketed) | Lower than Tier 3 | Moderate | Full | Full |
| 3 Standard PPD oxidative (box dye, salon) | Highest | High | Full | Full |
Anyone buying Tier 2 thinking they are getting biomimetic chemistry has been misled by marketing. Anyone choosing avocado-oil dyes specifically to be PPD-free should know the formulation still contains peroxide and TDS. Match the chemistry to the actual goal: full color range and fast coverage means Tier 3, lower allergy risk with full range means Tier 2, and brown-to-dark grey coverage with minimal shaft damage means Tier 1. The phrase 'natural hair dye' covers all three tiers in marketing copy and means almost nothing on its own. PPD free hair dye covers Tiers 1 and 2. Ammonia free hair dye covers Tier 1 and most of Tier 2. Only Tier 1 is actually biomimetic. The best hair dye for sensitive scalp users is almost always Tier 1, because the absence of peroxide and aromatic amines removes most of the irritation surface area. Read the INCI, not the front of the box. The choice between permanent vs semi permanent hair dye matters less than the choice between Tier 1, 2, and 3 chemistries.
Plantur 39 Anti-Grey vs hair dye vs leaving it alone the buyer guide
If you have mild-to-moderate greying and you are choosing between the Plantur 5,6-DHI line, conventional oxidative dye, and leaving it alone, here are the five questions and the honest answers.
Q2: How long does the color last?
It is a layered system, and the two layers behave differently. The HC dye top note in the Shampoo SKU fades in 6 to 10 washes, which is standard semi-permanent direct-dye behavior. The indole polymer base note builds visibly over 2 to 4 weeks of regular use, is wash-resistant, but photo-bleaches in UV and degrades in chlorine. Eumelanin polymers are not UV-stable, whether grown in your follicle or built on the shaft from a bottle. Heat styling is fine.
If you stop using it, the HC component fades out in roughly 2 weeks. The indole polymer fades more slowly with sun exposure and grows out at roughly 1cm per month. Obvious grey returns 4 to 6 weeks after stopping. Plantur's 'permanent / does not wash out, only grows out' claim is marketing-flattering. The honest description is closer to semi-permanent: durable on the shaft, but not a one-and-done pigment lock.
Q1: Does Plantur Anti-Grey work shaft-only or root-active?
Shaft-only. Plantur Anti-Grey 5,6-DHI deposits on already-grown hair shaft and auto-oxidizes there into eumelanin polymer. It does not travel to the follicle, and it does not cause new hair to grow in pigmented. Greying is an upstream stem-cell defect at the melanocyte level, not a deficiency the shaft can correct. New grey grows in grey. You must keep applying. Plantur's own FAQ language confirms this honestly: the pigment 'does not wash out but grows out with the hair.' That is shaft chemistry, not follicle therapy.
Q3: Does it damage the cuticle?
Substantially less than permanent oxidative dye. Plantur Anti-Grey runs at near-neutral pH (citric and phosphoric buffered) versus permanent dye at pH 9.5 to 10.5. The oxidant is atmospheric oxygen, not peroxide. There is no ammonia and no ethanolamine. Disulfide bonds and the 18-MEA cuticle lipid stay intact. This matters because almost everything that makes permanent dye damaging is missing here.
The honest caveats: SLS sits high on the INCI in the Shampoo SKU, which is harsh on already-dyed hair and on irritation-prone scalps. HC Blue No. 2 has theoretical EU nitrosamine concerns at high cumulative exposure, not at consumer use levels. 5,6-DHI itself is not on standard hairdresser baseline patch test series; documented contact allergy reports are sparse and orders of magnitude rarer than PPD or PTD reactions. This is one of the cleanest 5,6-DHI hair dye profiles on the consumer market, but 'cleaner' is not 'free of irritants.'
Q4: Does it damage the follicle or scalp?
No published evidence of follicle damage or unintended scalp pigmentation at consumer concentrations. The polymer formed on skin is the same chemistry as the eumelanin your own epidermis produces. The real risks are mundane and shared with most leave-on hair products: SLS irritation potential, and oxidized fragrance allergens (limonene, linalool, citronellol) for users with established fragrance sensitivity.
Q5: For a man with dark hair, dark beard, and mild greying, which option?
Scalp hair pick: Plantur 39 Anti-Grey Colouring Conditioner 1 to 2 times per week, with the Anti-Grey Shampoo on washes between. The Conditioner is the better DHI delivery vehicle: higher indole loading, leave-on contact of roughly 10 minutes, and a lower-surfactant base. The Shampoo is the maintenance SKU after the Conditioner has built a visible base layer. Plantur cannot disguise dense grey. The chemistry works on mild grey only. The upside is no peroxide, graceful growth-out with no demarcation line, and effectively no PPD allergy risk. This makes it one of the best practical options for a sensitive scalp user with dark hair.
Beard: Do not use Plantur on the beard. It is the wrong tool, for reasons covered in the next section.
Comparison table
Plantur Anti-Grey (5,6-DHI line)
- Effort per year
- Low (1-2x/week)
- Damage per year
- Low
- Allergy risk
- Low
- Reversibility
- Excellent (grows out clean)
Permanent vs semi permanent hair dye (box or salon)
- Effort per year
- Moderate (every 4-6 weeks)
- Damage per year
- High (cuticle, cortex, lipids)
- Allergy risk
- Moderate to high (PPD/PTD)
- Reversibility
- Pigment grows out, cuticle damage persists
Leave it alone
- Effort per year
- None
- Damage per year
- None
- Allergy risk
- None
- Reversibility
- Not applicable
The honest plantur 39 review reads: works as advertised on mild grey, fails to disguise dense grey, gentler on the shaft than any ammonia-free dye in Tier 2, and graceful to stop using. For someone shopping for the best hair dye for sensitive scalp use with dark hair and mild grey, the Plantur Anti-Grey line and a deliberate hairprint review comparison are the two products worth evaluating before stepping into Tier 2 oxidative chemistry.
Beard greying the case for and against dyeing
Beard greying is not the same problem as scalp greying. The skin is facial, not scalp. The exposure zone is the eating and breathing zone, which matters for any chemistry that off-gases or migrates. The aesthetic norms are different: salt-and-pepper on a beard reads naturally at low density, in a way that mid-scalp grey usually does not. And most products marketed as 'best beard dye' are aggressive PPD formulations rather than gentler alternatives.
- aesthetic check first
- allergy protocol second
- formula choice third
The case for leaving it alone
At low-to-moderate grey density, under roughly 30 percent grey, salt-and-pepper reads as distinguished, not old. The aesthetic argument comes first because most men jump to the chemistry question without checking it. A dense, uniform brown beard from dye reads more artificial than scattered grey. The visual contrast of pigmented and unpigmented hairs is information the eye reads as authentic. Removing that contrast often looks worse, not better.
The case against Just For Men specifically
Just For Men M-series uses PPD. The FDA Adverse Event Reporting System saw a sharp rise in facial-dye adverse event reports between 2014 and 2019, with Just For Men the most reported product in that window. Arm patch tests do not predict facial reactions reliably. Facial skin has different permeability, and eyelid involvement during a beard application is a real risk an arm test cannot model. Multiple lawsuits have documented severe contact dermatitis cases, including chemical burns and facial swelling. The honest answer to is just for men safe is: at population level, less safe than the alternatives, and a meaningful subset of users develop sensitization with repeat use.
If you must dye
Choose a beard-specific PPD-free or PTD-reduced formula. Bigen Speedy uses a different aromatic amine chemistry with fewer documented reactions. Henna-based beard kits contain no aromatic amines, but the color range is limited and red staining on grey hair is the realistic outcome, not natural brown. Mandatory protocol: 48-hour facial-margin patch test on the jawline or behind the ear before full application. Repeat the patch test every single dye session. Sensitization can develop after years of uneventful use, and the first severe reaction is often in someone who has used the product safely for a decade. A beard dye allergic reaction on the face is not the same problem as one on the scalp; the eyes and airway are inches away. Any beard dye allergic reaction that involves swelling, blistering, or visual changes is an emergency-room presentation, not a topical-cream problem.
Why Plantur Anti-Grey does not work on beards
Wrong tool for the job. Contact time on a beard during normal washing is seconds, not the 10 minutes the Colouring Conditioner needs to load indoles into the shaft. Beard hair density is wrong as well: sparser than scalp hair, with shorter average length, which makes it harder for the indole polymer to build coverage worth seeing. Plantur is not formulated, tested, or labeled for facial use, and using it there is off-label by definition.
Recommendation
For dark hair plus dark beard plus mild grey: leave the beard alone, and use Plantur 39 Anti-Grey on the scalp. The asymmetry reads more naturally than dyeing both, because scalp coverage and beard salt-and-pepper are both visually credible on their own. If beard grey crosses a personal threshold (call it more than 40 to 50 percent grey, and the look genuinely bothers you), the best beard dye available is a beard-specific PPD-free formula with mandatory 48-hour facial patch testing every session, not the most-advertised box on the shelf. The order of operations is: aesthetic check first, allergy protocol second, formula choice third. Most men benefit from stopping at step one.
Shedding Mechanism
The stress-cortisol-hair axis
Hair shedding driven by stress and hair loss is mechanistically distinct from androgenetic alopecia. The condition has a name (telogen effluvium) and the underlying biology is well-characterized. Confusing the two leads to bad decisions: people start finasteride for a problem that would have resolved on its own, or they ignore correctable upstream drivers because they assume their shedding is genetic.
- illness
- surgery
- childbirth
- severe rapid weight loss
- significant psychiatric stress
The hair cycle in 30 seconds
Each follicle moves through three phases. Anagen is the active growth phase, lasting roughly 2 to 7 years depending on body site and genetics. Catagen is a brief regression phase of about 2 to 3 weeks. Telogen is a resting phase of 2 to 3 months, after which the hair sheds and a new anagen begins. On a healthy scalp, roughly 85 percent of follicles sit in anagen, about 1 percent in catagen, and around 14 percent in telogen at any given moment. Daily shedding of 50 to 150 hairs is normal and is not a sign of pathology.
Telogen effluvium mechanism
Acute physiological stress (illness, surgery, childbirth, severe rapid weight loss, or significant psychiatric stress) pushes a synchronized cohort of follicles prematurely from anagen into catagen and telogen. The visible shed appears roughly 2 to 3 months later, when those telogen hairs reach the end of their resting phase and release together. Daily shedding rises to 200 to 500 hairs and is often dramatic enough to be noticed in the shower drain or on the pillow. The trigger event sits about three months upstream of the visible shed, which is why most people do not initially connect the two.
Cortisol mechanism
Chronic cortisol hair loss (from Cushing's syndrome, sustained psychological stress, or prolonged aggressive dieting) suppresses follicular sulfotransferase activity, which is the same enzyme system that activates topical minoxidil into its functional metabolite. Chronic cortisol also shifts the anagen-to-telogen ratio adversely and contributes to perifollicular inflammation. The result is a thinner, slower-cycling follicle population that sheds more readily and regrows less robustly.
The 'hair loss with weight loss' trap
Severe caloric restriction is one of the most common avoidable shedding triggers. Sustained intake under roughly 1,200 kcal per day for women or 1,500 kcal per day for men reliably induces telogen effluvium roughly three months in. Iron depletion and elevated cortisol from the restriction itself compound the effect. Anyone two months into an aggressive cut and not yet seeing shedding has not escaped the risk; the visible shed simply has not arrived yet.
Iron deficiency and ferritin
approximately 70 ng/mL ferritin, below which telogen effluvium tracks
Ferritin below approximately 70 ng/mL is associated with telogen effluvium across multiple observational studies. When iron deficiency hair loss is the proximate cause, repletion can reverse the shed. The important caveat is iron should not be supplemented blindly. Excess iron is toxic, and self-treatment without bloodwork is a poor strategy. A simple ferritin and CBC panel resolves the question.
Thyroid
above roughly 4.5 mIU/L TSH worth investigating
Hypothyroidism produces diffuse hair thinning and is a separate medical workup. A TSH above roughly 4.5 mIU/L is worth investigating with a clinician. Thyroid hair loss is screenable with a single blood draw before any cosmetic intervention is considered.
What helps
The intervention for telogen effluvium is to address the upstream cause. Recover from the triggering event, stabilize body weight, return to caloric adequacy, prioritize sleep, correct ferritin, B12, and vitamin D if deficient, and treat thyroid disease if present. Telogen effluvium typically self-resolves 6 to 12 months after the trigger ends, with full regrowth in most cases.
The honest closer
Telogen effluvium is recoverable. Androgenetic alopecia, without intervention, is not. The mechanisms are entirely different and the treatments are different. If your shed accelerated 2 to 3 months after a stressful event, surgery, illness, childbirth, or an aggressive diet, the most likely diagnosis is telogen effluvium rather than pattern hair loss. Stress and hair loss are connected through a defined biological axis, and cortisol-driven hair loss responds to addressing the cortisol driver, not to anti-androgen therapy.
Regrowth and greying Mechanism
The metabolic angle oxidative stress, mitochondria, and your hair
Hair follicles are among the most metabolically active tissues in the body. Mitochondrial dysfunction and oxidative stress at the follicle level are increasingly recognized as upstream drivers of both miniaturization in androgenetic alopecia and pigment loss in greying. This is the angle the BellyProof framework prioritizes, because it connects hair to the rest of the body's biology rather than treating the scalp as an isolated cosmetic compartment.
- visceral adiposity
- insulin resistance
- chronic low-grade inflammation
- smoking
- poor sleep
- adequate protein, roughly 1 g/kg
- sleep
- exercise
- reducing visceral adiposity
The follicle as a high-metabolic-demand tissue
Anagen-phase matrix keratinocytes proliferate at one of the highest rates of any cell population in the human body, comparable to intestinal crypt cells and bone marrow. Energy demand is correspondingly high, and mitochondrial output translates directly to hair shaft quality and cycling. A follicle that cannot meet its ATP demand cycles poorly, miniaturizes earlier, and produces thinner shafts.
PP405 reframed as metabolic biology
PP405, covered in the emerging treatments section, works by metabolically reprogramming follicle stem cells. The mechanism forces a glycolytic shift and wakes dormant stem cells from quiescence. This matters for the broader argument because PP405 is a metabolic pathway intervention, not a hormonal one. The fact that an investigational drug targeting follicle metabolism produces a clinical signal suggests the metabolic angle has real treatment potential, not just theoretical appeal.
Oxidative stress at the follicle level
The same oxidative biology that explains greying applies to non-pigment-producing follicle cells. Hydrogen peroxide accumulation, documented in the Wood 2009 and Shi 2014 lineage of work and covered in the greying section, damages mitochondrial DNA, lipids, and structural proteins. Across decades, this oxidative load compounds and pushes follicles toward miniaturization or telogen-dominance Trueb RM. Exp Gerontol 2017 Trueb 2017. Oxidative stress hair loss is not a marketing term; it is a documented contributor to the slow drift in hair density that begins well before clinically obvious pattern loss.
The systemic connection
Chronic systemic oxidative load raises follicle-level oxidative load. Visceral adiposity, insulin resistance, chronic low-grade inflammation, smoking, poor sleep, and sedentary lifestyle all elevate the oxidative burden the follicle has to process while also doing its day job. Metabolic hair loss, in this framing, is the slow downstream consequence of metabolic dysfunction expressed at a follicular endpoint. The BellyProof framework treats the metabolic load systemically (with mechanism-driven training, sleep, and nutrition) rather than addressing it cosmetically at the scalp. See the anti-aging master guide for the broader framework.
Mitochondrial nutrients with reasonable rationale
Several supplements have a defensible mitochondrial mechanism without yet having hair-specific RCT data. CoQ10 supports complex I-III electron transport. PQQ has a signal for mitochondrial biogenesis. GlyNAC, the combination of glycine and N-acetylcysteine, supplies the substrates for endogenous glutathione synthesis and has a small but interesting set of human aging trials. The honest framing is these compounds have systemic anti-aging signal, and any hair-specific benefit is extrapolation from upstream biology rather than direct trial evidence. Do not oversell, and do not expect a 4-week density change.
The diet and lifestyle layer that matters more
The interventions with the strongest mechanistic claim on hair quality are unglamorous. Adequate protein intake, with a floor of roughly 1 g/kg body weight per day, supplies the amino acid substrate for keratin synthesis. Sleep matters because the largest growth hormone pulse of the 24-hour cycle occurs during slow-wave sleep, and growth hormone signaling participates in follicle cycling. Exercise improves scalp microcirculation and reduces systemic inflammation. Reducing visceral adiposity lowers the systemic oxidative and inflammatory load the follicle has to absorb. Mitochondria hair loss is reversed, to whatever extent it is reversible, by upstream metabolic competence rather than topical exotica. Metabolic hair loss and oxidative stress hair loss are not interchangeable terms, but they share most of the same upstream drivers, and addressing one materially helps the other.
What this means practically
The metabolic angle is real but slow. You should not expect a measurable density change from a month of glutathione supplementation. You should expect long-term hair quality to track overall metabolic health, in the same way skin quality, energy, and recovery do. Hair is a downstream signal of systemic biology, and treating it as a standalone problem misses where the leverage actually sits. The systemic-biology work that drives the downstream signal (sleep, stress, metabolic health) lives inside the wider BellyProof program, and if you want structured guidance you can join BellyProof from there.
Washing Practice
How often should you actually wash your hair?
Most wash-frequency advice is too generic to be useful. 'Wash every day' and 'never wash' are both wrong for most people. The right frequency depends on what the scalp produces, what you are trying to optimize for, and the hair's structural type. This section is segmented accordingly. The honest answer to how often should i wash my hair is conditional, not universal, and the related question of is shampoo bad for your hair has the same conditional shape.
By hair type baseline
Oily and straight hairdaily or every-other-day
Oily and straight hair, including fine straight Caucasian or East Asian hair textures, generally needs daily or every-other-day washing. Sebum migrates rapidly along straight shafts and the hair looks greasy quickly.
Dry and curly hair3 to 7 day cycle
Dry and curly hair typically does best on a 3 to 7 day cycle. Sebum cannot migrate efficiently down curl spirals, so the lengths run dry while the scalp may sit oily. Co washing hair, which is conditioner-only cleansing between shampoo washes, fits this pattern well.
Coarse, coily, or Type 4 textured hairweekly or longer
Coarse, coily, or Type 4 textured hair often does best on a weekly or longer cycle. Moisture retention is the priority and over-washing strips an already fragile texture.
By condition
Hair loss and thinning. Daily or near-daily washing with a gentle shampoo is generally fine, and ketoconazole 2 percent shampoo 2 to 3 times per week is a reasonable adjunct. Sebum buildup at the follicular ostium can plausibly trap DHT and inflammatory mediators, so heavy under-washing is not a hair-loss strategy. The 'stop washing your hair' social media trend does not help androgenetic alopecia.
Greying. Wash frequency does not affect pigment biology. If you are using Plantur 39 Anti-Grey or another leave-on conditioner, the product sits on the hair for roughly 10 minutes and then washes out at your normal frequency, whatever that is. UV exposure between washes affects color stability of grey hair more than wash count does.
Healthy young hair maintenance. Default to the hair-type baseline above. Engineering an elaborate shampoo schedule to 'preserve' healthy hair is a marketing-driven anxiety, not a biological need.
Stress and cortisol-related shedding. Wash frequency is irrelevant to the mechanism. Address the upstream cortisol and recovery driver per the stress-cortisol section above.
Sebum: the basic biology
Sebaceous glands produce sebum continuously. On the scalp, sebum migrates down the hair shaft and conditions the hair naturally. Over-washing strips this layer and triggers rebound overproduction, leading to the well-known cycle of feeling like the hair gets greasy faster the more often it is washed. Under-washing allows sebum and desquamated cells to accumulate, which can cause flaking, irritation, and in some cases blocked follicular openings. Neither extreme is correct as a default.
The no-poo and co-washing question, honestly
Co-washing works well for very curly and coily hair where sebum cannot migrate down the shaft, because the conditioner provides the mechanical and lipid layer the hair needs without the surfactant strip. For oily, straight hair, co-washing causes scalp buildup and is usually a mistake. The no poo method is a tribal myth that gets misapplied across hair types when it should be a targeted strategy for specific textures. Co-washing is a tool, not a religion.
Shampoo choice matters more than frequency
The composition of the shampoo often matters more than how often it is used. Sulfate-free formulations using gentle surfactants such as cocamidopropyl betaine or decyl glucoside are appropriate for sensitive scalps. Sodium lauryl sulfate is reasonable for most scalps but should be avoided in irritation-prone individuals. Ketoconazole 2 percent 2 to 3 times per week is a modest but real adjunct in androgenetic alopecia, with anti-androgenic and anti-inflammatory effects at the scalp. Scalp oil management is biology, not ritual. The question of whether shampoo is bad for hair has the same answer as most cosmetic questions: the wrong shampoo for a given scalp is bad, the right shampoo is fine.
The honest summary
Match wash frequency to hair type, not to social media trends. Under-washing harms hair-loss management more often than over-washing does. How often should men wash hair receives the same answer as women: the answer depends on hair type and scalp output, not on gender.
The general rule is to engineer the mechanism, not the ritual.
Scientific References
Hair Graying Mechanisms and Biology
-
Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J. 2009;23(7):2065-2075. PubMed: 19237503
Massive epidermal H2O2 accumulation with reduction in catalase and MSRA/B expression in grey hair follicles
PubMed (opens in new tab) -
Dedifferentiation maintains melanocyte stem cells in a dynamic niche. Nature. 2023;616(7958):774-782. PubMed: 37100939
McSCs must dedifferentiate to maintain stemness; stuck cells between bulge and hair germ lose regenerative capacity
PubMed (opens in new tab) -
Nishimura EK. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res. 2011;24(3):401-410. PubMed: 21466661
Melanocyte stem cell dysfunction in graying
PubMed (opens in new tab) -
Hyperactivation of sympathetic nerves drives melanocyte stem cell depletion. Nature. 2020;577(7792):676-681. PubMed: 31969703
Norepinephrine from stressed sympathetic nerves depletes McSCs
PubMed (opens in new tab) -
Premature Graying as a Consequence of Compromised Antioxidant Activity in Hair Bulb Melanocytes and Their Precursors. PLoS One. 2014;9(4):e93589. PubMed: 24695442
Reduced catalase and increased H2O2 in grey vs pigmented follicles
PubMed (opens in new tab) -
Biology and clinical relevance of hair greying. Biol Chem. 2017;398(7):707-719. PubMed: 28650915
Hair graying biology and mechanisms
PubMed (opens in new tab) -
Hair Graying: Mechanisms, Prevention, and Innovative Treatment Strategies, literature review. ResearchGate. 2023.
Comprehensive review of graying mechanisms and treatments
Antioxidant Systems and Hair Graying Interventions
-
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89. PubMed: 36881848
100mg/kg/day dosing improved glutathione by 64% and reduced oxidative stress markers
PubMed (opens in new tab) -
Trueb RM. Oxidative stress and its impact on skin, scalp and hair. Int J Cosmet Sci. 2021;43(S1):S9-S13. PubMed: 34297395
Catalase activity decreases 10% per decade after age 20
PubMed (opens in new tab) -
Antioxidant peptides and hair pigment protection. Redox Biol. 2021;40:101858. PubMed: 34248927
Antioxidant peptides protect hair pigmentation
PubMed (opens in new tab) -
Kumar A. Reversal of Premature Hair Graying Treated with a Topical Formulation Containing α-Melanocyte-Stimulating Hormone Agonist (Greyverse Solution 2%). Int J Trichology. 2022;14(6):207.
α-MSH agonist showed reversal of premature graying
Androgenetic Alopecia Mechanisms
-
Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2017;89:43-49. PubMed: 30352735
DHT-mediated follicle miniaturization mechanisms
PubMed (opens in new tab) -
Kaufman KD. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin. 1996;14(4):697-711. PubMed: 15034519
5α-reductase conversion of testosterone to DHT
PubMed (opens in new tab) -
Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss. Br J Dermatol. 2006;155(5):926-930. PubMed: 17034521
Terminal to vellus hair ratio changes in androgenetic alopecia
PubMed (opens in new tab) -
Hair cycle and ethnicity. Dermatol Clin. 2021;39(3):347-355. PubMed: 34229862
2-6x variation in 5α-reductase activity between populations
PubMed (opens in new tab)
5α-Reductase Inhibitors (Finasteride and Dutasteride)
-
The importance of dual 5α-reductase inhibition: dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. PubMed: 17110217
Dutasteride 0.5mg reduces DHT by 90-94% at 24 weeks vs 70% for finasteride
PubMed (opens in new tab) -
Topical finasteride in androgenetic alopecia: Review and meta-analysis. Dermatol Ther. 2020;33(4):e13741. PubMed: 28016819
Topical finasteride efficacy and systemic absorption
PubMed (opens in new tab) -
Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review. Dermatology Reports. 2024;16(4).
Systematic comparison of dutasteride vs finasteride efficacy
-
Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study. Ann Dermatol. 2022;34(5):349-356.
Long-term comparative effectiveness data
Minoxidil Mechanisms and Applications
-
Efficacy and safety of minoxidil formulations in androgenetic alopecia. J Am Acad Dermatol. 2011;64(4):684-692. PubMed: 15373137
Minoxidil efficacy across different formulations
PubMed (opens in new tab) -
Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725-1736. PubMed: 18258787
Specific KATP channel subtype sensitivity to minoxidil
PubMed (opens in new tab) -
Minoxidil Promotes Hair Growth through Stimulation of Growth Factor Release from Adipose-Derived Stem Cells. Int J Mol Sci. 2018;19(3):691. PMC: 5877552
Growth factor release mechanism
PMC: 5877552 (opens in new tab) -
Minoxidil sulfotransferase enzyme activity determines minoxidil response. J Dermatol Sci. 2020;99(1):51-57. PubMed: 32563631
40% of non-responders have low follicular sulfotransferase activity
PubMed (opens in new tab) -
Randolph M, Tosti A. Oral minoxidil treatment for hair loss. J Am Acad Dermatol. 2021;84(3):737-746. PubMed: 32750432
Oral minoxidil 2.5-5mg daily effective with different side effect profile
PubMed (opens in new tab) -
Minoxidil for beard and chest hair: Off-label efficacy. Dermatol Ther. 2021;34(4):e14969. PubMed: 34450503
Off-label use for body hair enhancement
PubMed (opens in new tab) -
Efficacy of 3% minoxidil lotion for beard enhancement. J Dermatol. 2016;43(8):968-969. PubMed: 26853906
16-week trial showing significant beard density improvement
PubMed (opens in new tab)
Microneedling and Physical Interventions
-
Microneedling and its applications in dermatology. Indian Dermatol Online J. 2015;6(4):235-241. PubMed: 29171533
Microneedling applications in dermatology
PubMed (opens in new tab) -
English RS Jr, Barazesh JM. Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia. Dermatol Ther. 2022;12(1):41-60. PubMed: 34714536
Microneedling 0.5-1.5mm depth optimal for growth factor release without scarring
PubMed (opens in new tab) -
Dhurat R, Mathapati S. Response to Microneedling Treatment in Men with Androgenetic Alopecia. Int J Trichology. 2015;7(2):49-52. PubMed: 26180448
Microneedling + minoxidil superior to minoxidil alone (82% vs 4.5% response)
PubMed (opens in new tab) -
English RS Jr, Barazani SJ. Microneedling and Its Use in Hair Loss Disorders: A Systematic Review. Dermatol Ther. 2022;12(1):41-60. PMC: 8754113
Systematic review of microneedling effectiveness
PMC: 8754113 (opens in new tab) -
Microneedle fractional radiofrequency for hair growth. Dermatol Surg. 2020;46(12):1671-1677. PubMed: 32568741
3-fold increase in peptide penetration with microneedling
PubMed (opens in new tab)
Platelet-Rich Plasma (PRP) and Growth Factors
-
The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Transl Med. 2015;4(11):1317-1323. PubMed: 26400925
PRP shows significant improvement in hair regrowth
PubMed (opens in new tab) -
Gentile P, Garcovich S. Systematic review of PRP use in androgenetic alopecia. Biomedicines. 2020;8(8):237. PubMed: 32702519
25% improvement in hair density after 3 monthly PRP sessions
PubMed (opens in new tab) -
A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6-11. PubMed: 23960389
Microneedling efficacy in androgenetic alopecia
PubMed (opens in new tab)
Low-Level Light Therapy (LLLT)
-
Low-level laser (light) therapy for treatment of hair loss. Lasers Surg Med. 2019;51(4):299-308. PubMed: 30679525
LLLT mechanisms and clinical efficacy
PubMed (opens in new tab) -
The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med. 2013;45(8):487-495. PubMed: 24078483
Red light laser promotes hair growth in males
PubMed (opens in new tab) -
The growth of human scalp hair in males using 655nm red light. Lasers Surg Med. 2014;46(8):601-607. PubMed: 25124964
LLLT 655nm wavelength increases hair count by 20% at 26 weeks
PubMed (opens in new tab)
Peptide Therapies and Growth Factors
-
Peptide-based treatments for hair loss. Expert Opin Biol Ther. 2023;23(4):343-356. PubMed: 37037956
Peptide mechanisms in hair growth stimulation
PubMed (opens in new tab) -
Pickart L, Margolina A. The effect of GHK-Cu on hair growth. SOFW Journal. 2012;138(3):2-8.
GHK-Cu peptide effects on hair growth
-
Pickart L, Margolina A. Regenerative effects of GHK-Cu peptide. J Aging Res Clin Practice. 2018;7:34-39. PubMed: 29731700
GHK-Cu modulates 4,000+ genes and increases collagen by 70%
PubMed (opens in new tab) -
Microneedling with topical peptides for hair regrowth. J Dermatol. 2021;48(4):479-485. PubMed: 33263395
Synergistic effects of microneedling with peptides
PubMed (opens in new tab) -
Peptides and botanicals for scalp health. J Drugs Dermatol. 2021;20(4):406-412. PubMed: 33889276
Peptide and botanical combinations for scalp health
PubMed (opens in new tab) -
Effects of PDRN on hair growth. J Cosmet Dermatol. 2018;17(5):688-693. PubMed: 29663671
PDRN activates A2A receptors promoting anagen phase
PubMed (opens in new tab)
Natural and Botanical Treatments
-
Rosemary oil vs minoxidil 2% for androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15-21. PubMed: 25842469
Rosemary oil comparable efficacy to minoxidil 2%
PubMed (opens in new tab) -
Promotion of hair growth by Rosmarinus officinalis leaf extract. Phytother Res. 2013;27(2):212-217. PubMed: 22517595
Rosemary extract increases microcirculation by 35%
PubMed (opens in new tab) -
Peppermint oil promotes hair growth without toxic signs. Toxicol Res. 2014;30(4):297-304. PubMed: 24397881
Peppermint oil promotes hair growth
PubMed (opens in new tab) -
Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia. Evid Based Complement Alternat Med. 2014;2014:549721. PubMed: 24864154
Pumpkin seed oil benefits for androgenetic alopecia
PubMed (opens in new tab) -
Hair growth promoting effect of Zizyphus jujuba essential oil. Food Chem Toxicol. 2010;48(5):1350-1354. PubMed: 20206225
Essential oils mechanism through prostaglandin modulation
PubMed (opens in new tab) -
Human hair growth ex vivo is promoted by topical application of caffeine. Br J Dermatol. 2007;157(1):84-89. PubMed: 17576324
Caffeine blocks DHT-induced follicle damage at hair root
PubMed (opens in new tab) -
A new topical treatment for androgenetic alopecia. J Cosmet Dermatol. 2011;10(2):94-102. PubMed: 21649813
Niacinamide improves hair fullness and reduces inflammation
PubMed (opens in new tab) -
An Overview of Commonly Used Natural Alternatives for the Treatment of Androgenetic Alopecia, with Special Emphasis on Rosemary Oil. Clin Cosmet Investig Dermatol. 2024;17:451-462. PMC: 10158935
Comprehensive review of natural alternatives
PMC: 10158935 (opens in new tab) -
Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia. Skin Appendage Disord. 2020;6(6):329-337. PMC: 7706486
Saw palmetto systematic review for alopecia
PMC: 7706486 (opens in new tab)
Hormonal Influences and Hair Loss
-
Hair changes in menopause. Maturitas. 2019;126:61-65. PubMed: 31133234
Estrogen decline affects 50 percent of women hair density post-menopause
PubMed (opens in new tab) -
Hormonal effects on hair follicles. Int J Mol Sci. 2020;21(15):5342. PubMed: 32731328
16% of PCOS patients experience androgenetic alopecia
PubMed (opens in new tab) -
Thyroid disease and its impact on hair loss. Int J Trichology. 2021;13(4):142-149. PubMed: 34106751
Thyroid dysfunction effects on hair
PubMed (opens in new tab) -
Body hair and androgenic pathways. Front Endocrinol (Lausanne). 2020;11:586379. PubMed: 33092073
Androgenic pathways in body hair development
PubMed (opens in new tab) -
Non-hormonal therapies for female pattern hair loss. Dermatol Ther. 2022;35(11):e15741.
Non-hormonal treatment options for women
Stress and Hair Loss
-
Stress and the human hair follicle: Current perspectives. Exp Dermatol. 2021;30(2):219-228. PubMed: 30872041
Stress mechanisms affecting hair follicles
PubMed (opens in new tab) -
Telogen effluvium: New insights into a common disorder. J Drugs Dermatol. 2016;15(11):1392-1398. PubMed: 27879581
Telogen effluvium mechanisms and triggers
PubMed (opens in new tab) -
Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126(8):1697-1704. PubMed: 16845409
Neuroimmune stress effects on skin and hair
PubMed (opens in new tab) -
Corticosterone inhibits GAS6 to govern hair follicle stem-cell quiescence. Nature. 2021;592(7854):428-432. PubMed: 33790466
Cortisol suppresses Gas6 secretion preventing stem cell activation
PubMed (opens in new tab) -
Multi-therapies in androgenetic alopecia. Dermatol Ther. 2016;29(4):1523-1533. PubMed: 27426212
Percentage of stress-related telogen effluvium cases showing reversibility
PubMed (opens in new tab)
Hair Care Products and Ingredients
-
Corbett JF. Surfactants in shampoos: Scalp impact. Int J Cosmet Sci. 2015;37(4):406-413. PubMed: 25829710
Surfactant effects on scalp health
PubMed (opens in new tab) -
Preservatives and scalp sensitivity. J Cosmet Dermatol. 2016;15(3):344-351. PubMed: 27432047
Preservative-induced scalp sensitivity
PubMed (opens in new tab) -
AAD Guidelines for Androgenetic Alopecia. J Am Acad Dermatol. 2020;82(2):252-259. PubMed: 31891714
SLS causes scalp irritation in 30% of users
PubMed (opens in new tab) -
Gavazzoni MD. Hair cosmetics and hair shaft disorders. An Bras Dermatol. 2015;90(1):9-12. PubMed: 25672294
Non-water-soluble silicone buildup and follicle occlusion
PubMed (opens in new tab) -
Hair biology and cosmetics. Dermatol Clin. 2021;39(3):417-429. PubMed: 34053588
Cocamidopropyl betaine preserves barrier function
PubMed (opens in new tab) -
Updated 2021. CDC Link Key finding: Parabens detected in 90% of US population samples.
Parabens detected in 90% of US population samples
CDC Link (opens in new tab)
Advanced Hair Restoration Technologies
-
Hair follicle cloning for human transplantation. Nat Biotechnol. 2020;38(3):267-279. PubMed: 32161402
Unlimited follicle generation timeline 2027-2030
PubMed (opens in new tab) -
Exosome therapy for hair regeneration: Updates and advances. Int J Mol Sci. 2021;22(14):7466. PubMed: 33523246
Exosome therapy for hair regeneration
PubMed (opens in new tab) -
Extracellular vesicles in regenerative medicine. J Control Release. 2021;330:706-725. PubMed: 33388343
Exosomes carry miRNAs and growth factors for regeneration
PubMed (opens in new tab) -
Clinical efficacy of exosome therapy in alopecia. Stem Cell Res Ther. 2022;13:401. PubMed: 35922875
Exosome therapy available at select clinics worldwide
PubMed (opens in new tab) -
Stemson Therapeutics Key finding: iPSC-derived follicles in humanized mice, human trials 2026.
iPSC-derived follicles in humanized mice, human trials 2026
Link (opens in new tab)
Metabolic and Mitochondrial Pathways
-
Targeting mitochondrial metabolism for hair regrowth: PP405 and beyond. Trends Mol Med. 2022;28(12):1076-1089. PubMed: 36193790
Mitochondrial metabolism targets for hair regrowth
PubMed (opens in new tab) -
MPC inhibition reactivates dormant hair follicle stem cells. Cell Rep. 2022;39(2):110651. PubMed: 35540978
MPC inhibition shifts metabolism toward regeneration
PubMed (opens in new tab) -
Pyruvate metabolism, lactate, and hair cycling. Nat Commun. 2023;14(1):2466. PubMed: 37126052
Lactate production increases stem cell proliferation
PubMed (opens in new tab) -
Mitochondrial pyruvate carrier function in hair follicles. Cell Metab. 2023;35(3):513-528. PubMed: 36889283
MPC inhibition shifts metabolism toward regeneration
PubMed (opens in new tab) -
Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol. 2017;19(9):1017-1026. PubMed: 28812580
Glycolytic metabolism promotes stem cell activation
PubMed (opens in new tab) -
Molecular mechanisms of dermal aging. Int J Mol Sci. 2019;20(9):2126. PubMed: 31027339
Lactate production increases stem cell proliferation
PubMed (opens in new tab)
Emerging Clinical Targets
-
Stem cell activation in clinical hair regrowth. J Clin Invest. 2023;133(8):e167845. PubMed: 37000408
Clinical stem cell activation approaches
PubMed (opens in new tab) -
Phase 2a PP405 Results. June 2024. Pelage Pharma Key finding: 31% response rate at 8 weeks, Phase 3 planned 2026.
31% response rate at 8 weeks, Phase 3 planned 2026
Pelage Pharma (opens in new tab) -
The Effects of Negative Pressure Therapy on Hair Growth of Mouse Models. Tissue Eng Part A. 2024. ResearchGate
Negative pressure therapy effects on hair growth
ResearchGate (opens in new tab)
Additional Clinical Studies and Meta-Analyses
-
Canities: Etiology, pathogenesis, and treatment. Indian J Dermatol Venereol Leprol. 2021;87(6):780-789. PubMed: 34736824
Comprehensive canities review
PubMed (opens in new tab) -
Potential reversibility of grey hair: case studies and mechanisms. J Cosmet Dermatol. 2022;21(4):1442-1448. PubMed: 34982082
Case studies of grey hair reversibility
PubMed (opens in new tab) -
Non-hormonal treatments for hair loss. Int J Mol Sci. 2019;20(24):6317. PubMed: 30662346
Non-hormonal treatment options
PubMed (opens in new tab) -
Role of oral minoxidil in androgenetic alopecia. Ann Dermatol. 2022;34(5):349-356. PubMed: 36082742
DHT tissue level variations between ethnic populations
PubMed (opens in new tab) -
Minoxidil Use in Children and Adolescents. J Dermatolog Treat. 2022;33(2):680-684. PubMed: 32702261
Case studies of minoxidil for body hair enhancement
PubMed (opens in new tab)
Disease Associations and Environmental Factors
-
Sinclair RD. Alopecia areata and metabolic syndrome. J Dermatol. 2018;45(5):515-521. PubMed: 29569276
4x increased metabolic syndrome in early-onset AGA
PubMed (opens in new tab) -
Environmental factors in hair loss. Int J Trichology. 2021;13(1):1-9. PubMed: 33850393
UV and pollution effects on follicle oxidative stress
PubMed (opens in new tab) -
Human scalp hair as a thermoregulatory adaptation. Proc Natl Acad Sci U S A. 2023;120(15):e2301760120. PNAS
Hair as thermoregulatory adaptation
PNAS (opens in new tab)
Combination Therapies and Treatment Outcomes
-
Network meta-analysis of efficacy of treatments for AGA. J Cosmet Dermatol. 2022;21(7):2810-2818. PubMed: 35146884
Combination therapies show 30-40% improved outcomes
PubMed (opens in new tab) -
Cannabinoids and the skin. J Am Acad Dermatol. 2022;87(1):1-10. PubMed: 35256196
CBD modulates inflammatory pathways in scalp
PubMed (opens in new tab)
DHT Paradox and Androgen Receptor Biology (added 2026-05)
-
5-alpha-reductase activity in hair follicles of frontal and occipital scalp. J Invest Dermatol. 1996;106(6):1342-1345. PubMed: 9558487
5-alpha reductase Type II concentrated heavily in scalp dermal papilla; the foundational enzyme-density paper for the DHT paradox
PubMed (opens in new tab) -
Molecular basis of androgenetic alopecia: from androgen to paracrine mediators through dermal papilla. Exp Dermatol. 2013;22(3):169-173.
Higher AR density in balding frontal/vertex DP than beard or occipital DP. The flipped DP cell secretome (beard DP secretes IGF-1 under DHT vs balding DP secretes TGF-beta1, TGF-beta2, DKK-1, IL-6 under same DHT) is the mechanistic core of the paradox
Wiley (opens in new tab) -
Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116(3):452-455. PubMed: 11231320
AR CAG-repeat polymorphism: shorter CAG repeats produce a more transcriptionally sensitive androgen receptor; men with shorter AR CAG are over-represented in early-onset AGA
PubMed (opens in new tab)
Mechanical Tension Theory (Galea Aponeurotica)
-
A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. Med Hypotheses. 2018;111:73-81. PubMed: 29407002
Finite-element-style hypothesis paper proposing chronic galeal tension drives mechanotransduction-mediated, site-specific inflammation, fibrosis/calcification, and follicle miniaturization in the AGA pattern
PubMed (opens in new tab) -
Cause of androgenic alopecia: crux of the matter. Plast Reconstr Surg Glob Open. 2013;1(7):e64. PMC: 4639964
Older gravitational scalp tension hypothesis; finite-element analysis of stress distribution in the galea matches AGA progression pattern
PMC: 4639964 (opens in new tab) -
Standardized Scalp Massage Results in Increased Hair Thickness by Inducing Stretching Forces to Dermal Papilla Cells in the Subcutaneous Tissue. Eplasty. 2016;16:e8. PMC: 4740347
4 min/day standardized scalp massage for 24 weeks in 9 men: hair shafts thickened measurably; in vitro DP cells under cyclic stretch upregulated NOGGIN, BMP4, SMAD4 and downregulated IL-6. N=9, single-arm, no control
PMC: 4740347 (opens in new tab) -
Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34. PubMed: 22440736
PGD2 levels 3x higher in bald scalp; transgenic K14-Ptgs2 mice develop AGA-like phenotype. PGD2 is a marker of inflamed environment in AGA
PubMed (opens in new tab) -
Botulinum toxin in male pattern hair loss: a triple-blind randomized controlled trial. J Am Acad Dermatol. 2024;91(6):1057-1064. PubMed: 39047987
First properly controlled RCT on botox for AGA. NO benefit found; terminal hair density numerically decreased in botox arm. Supersedes earlier uncontrolled positive series
PubMed (opens in new tab) -
A randomized, placebo-controlled trial of setipiprant for androgenetic alopecia. PMC8526366. 2018
Phase 2a setipiprant (CRTH2/PGD2 antagonist) in AGA: adequate scalp tissue drug levels but FAILED primary efficacy endpoint. Allergan/AbbVie program shelved
PMC: 8526366 (opens in new tab)
Evidence-Tier Treatment References
-
Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-194. PubMed: 14996087
KATP channel opening, growth factor release, anagen prolongation
PubMed (opens in new tab) -
A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia. Int J Trichology. 2013;5(1):6-11. PMC: 3746236
N=100, 12 weeks: weekly microneedling + 5% minoxidil BID added +91.4 hairs/cm-squared vs +22.2 minoxidil alone; 82% vs 4.5% reported >50% improvement
PMC: 3746236 (opens in new tab) -
Low-dose oral minoxidil for AGA: meta-analysis (PMC10806356). 2024
17 single-arm + 10 RCT studies, n=2,933, doses 0.25-5mg/day. LDOM equivalent or superior to topical on several endpoints; ~15% hypertrichosis, 1.3-10% fluid retention
PMC: 10806356 (opens in new tab) -
JAAD expert consensus on low-dose oral minoxidil 2024. JAAD 2024. PubMed: 39729337
Formal consensus legitimizing off-label LDOM for AGA
PubMed (opens in new tab) -
Topical finasteride 0.25% spray for AGA: Phase 3 RCT. JEADV. 2022. PMC9297965
Comparable efficacy to oral; scalp DHT down 50-70%, serum DHT down 25-50% (vs >90% oral). Approved in EU; FDA open safety questions June 2025
PMC: 9297965 (opens in new tab) -
Comparative effectiveness of low-level laser therapy for hair loss. Lasers Med Sci. 2019. PubMed: 30706177
Meta-analysis SMD 1.32 for hair density; FDA-cleared devices both sexes; modest as adjunct
PubMed (opens in new tab) -
Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. Int J Dermatol. 2007;46(1):27-35. PubMed: 17214716
Ex vivo organ culture, 14 vertex biopsies; caffeine reversed testosterone-suppressed follicle elongation. Foundational mechanism paper for caffeine shampoo claims
PubMed (opens in new tab) -
Topical caffeine on hair follicle TGF-beta2 / IGF-1. Br J Dermatol. 2014;171(5):1031-1043. PubMed: 24836650
Caffeine modulates TGF-beta2 and IGF-1 in follicle culture
PubMed (opens in new tab) -
Platelet-rich plasma for androgenetic alopecia: meta-analysis (43 RCTs). Dermatol Ther. 2025
n=1,877. PRP > placebo, non-significant difference vs minoxidil, PRP+minoxidil > either alone. Heterogeneous prep protocols remain the field problem
Springer (opens in new tab)
Inflated/Marketed Compound Citations
-
A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169. PMC: 5582478
Zero RCT evidence for biotin in non-deficient users
PMC: 5582478 (opens in new tab) -
Biotin in hair and skin: 2024 systematic review update. JCAD. 2024. PubMed: 39148962
Reaffirms zero RCT evidence in non-deficient users; biotin also interferes with TSH/troponin lab assays
PubMed (opens in new tab) -
Onion juice (Allium cepa L.), a new topical treatment for alopecia areata. J Dermatol. 2002;29(6):343-346. PubMed: 12126069
N=23, 86.9% regrowth at 6 weeks in alopecia areata. Unrandomized, unblinded, never replicated in 23 years; AA-specific not AGA
PubMed (opens in new tab) -
Inhibition of 5-alpha reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988;119(5):627-632. PubMed: 3207614
Zinc inhibits 5-alpha reductase in vitro; foundational paper for zinc PCA claims (no human topical AGA RCT exists)
PubMed (opens in new tab)
Pigment Biology and Greying Mechanisms (additions)
-
Quantitative mapping of human hair greying and reversal in relation to life stress. eLife. 2021;10:e67437
High-resolution proteomic mapping along single hair shafts correlated to time-stamped life events. Hairs greyed during stress, repigmented when stress dropped, mostly in middle-aged subjects near greying threshold. Bounded reversibility window
eLife (opens in new tab)
Biomimetic Dye Chemistry (5,6-DHI / Eumelanin)
-
Melanin biopolymers from chemistry to materials science. Int J Mol Sci. 2018;19(6):1753
Foundational eumelanin-pathway chemistry: tyrosine to DOPA to dopaquinone to DHI/DHICA to eumelanin polymer (Raper-Mason pathway). 5,6-DHI is the penultimate intermediate in oxidative polymerization; basis for biomimetic hair dye chemistry
MDPI (opens in new tab) -
Para-phenylenediamine allergy: current perspectives on diagnosis and management. J Asthma Allergy. 2017;10:9-15. PMC: 5261844
PPD as the leading cosmetic contact dermatitis trigger globally; cross-reactivity with related aromatic amines including TDS
PMC: 5261844 (opens in new tab) -
Mechanisms of impairment in hair and scalp induced by hair dyeing. Frontiers in Medicine. 2023;10:1139607
Documented permanent oxidative dye damage: cuticle lifting, cortex protein loss, lipid stripping including 18-MEA depletion
Frontiers (opens in new tab)
